WO2016047715A1 - 腫瘍抗原ペプチド - Google Patents
腫瘍抗原ペプチド Download PDFInfo
- Publication number
- WO2016047715A1 WO2016047715A1 PCT/JP2015/076994 JP2015076994W WO2016047715A1 WO 2016047715 A1 WO2016047715 A1 WO 2016047715A1 JP 2015076994 W JP2015076994 W JP 2015076994W WO 2016047715 A1 WO2016047715 A1 WO 2016047715A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hla
- peptide
- seq
- polypeptide
- boris
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 607
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 216
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 253
- 102000036639 antigens Human genes 0.000 title abstract description 69
- 108091007433 antigens Proteins 0.000 title abstract description 68
- 239000000427 antigen Substances 0.000 title abstract description 66
- 201000011510 cancer Diseases 0.000 claims abstract description 158
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 66
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 66
- 239000002157 polynucleotide Substances 0.000 claims abstract description 66
- 238000011282 treatment Methods 0.000 claims abstract description 42
- 210000000130 stem cell Anatomy 0.000 claims abstract description 41
- 239000004480 active ingredient Substances 0.000 claims abstract description 40
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 claims abstract description 35
- 230000002265 prevention Effects 0.000 claims abstract description 31
- 230000036961 partial effect Effects 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 230000001939 inductive effect Effects 0.000 claims abstract description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 332
- 210000004027 cell Anatomy 0.000 claims description 322
- 229920001184 polypeptide Polymers 0.000 claims description 205
- 238000000034 method Methods 0.000 claims description 123
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 claims description 72
- 150000001413 amino acids Chemical class 0.000 claims description 60
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 35
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 30
- 108010036972 HLA-A11 Antigen Proteins 0.000 claims description 27
- 239000000411 inducer Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 18
- 201000005202 lung cancer Diseases 0.000 claims description 18
- 208000020816 lung neoplasm Diseases 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 239000013604 expression vector Substances 0.000 claims description 17
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 16
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 210000000056 organ Anatomy 0.000 claims description 9
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 7
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims description 2
- 238000002331 protein detection Methods 0.000 claims description 2
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 238000004458 analytical method Methods 0.000 description 96
- 239000003153 chemical reaction reagent Substances 0.000 description 83
- 239000000523 sample Substances 0.000 description 75
- 230000014509 gene expression Effects 0.000 description 65
- 102000011786 HLA-A Antigens Human genes 0.000 description 56
- 108010075704 HLA-A Antigens Proteins 0.000 description 56
- 230000006698 induction Effects 0.000 description 56
- 108010029485 Protein Isoforms Proteins 0.000 description 45
- 102000001708 Protein Isoforms Human genes 0.000 description 45
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 43
- 235000001014 amino acid Nutrition 0.000 description 41
- 229940024606 amino acid Drugs 0.000 description 41
- 238000010586 diagram Methods 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 34
- 238000012360 testing method Methods 0.000 description 32
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 29
- 206010008342 Cervix carcinoma Diseases 0.000 description 27
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 27
- 201000010881 cervical cancer Diseases 0.000 description 27
- 239000013598 vector Substances 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 20
- 206010033128 Ovarian cancer Diseases 0.000 description 19
- 206010061535 Ovarian neoplasm Diseases 0.000 description 19
- 108010077497 KLA peptide Proteins 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 239000013642 negative control Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 13
- 108020004459 Small interfering RNA Proteins 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 238000012258 culturing Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 13
- 108010002350 Interleukin-2 Proteins 0.000 description 12
- 230000001472 cytotoxic effect Effects 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 108010004729 Phycoerythrin Proteins 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 208000002495 Uterine Neoplasms Diseases 0.000 description 10
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 10
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 10
- 206010046766 uterine cancer Diseases 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000010230 functional analysis Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- -1 NANOG Proteins 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 7
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 7
- 210000003969 blast cell Anatomy 0.000 description 7
- 210000004748 cultured cell Anatomy 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 238000002493 microarray Methods 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 230000030741 antigen processing and presentation Effects 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 5
- 238000010195 expression analysis Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 101800001415 Bri23 peptide Proteins 0.000 description 4
- 101800000655 C-terminal peptide Proteins 0.000 description 4
- 102400000107 C-terminal peptide Human genes 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 241000702421 Dependoparvovirus Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000711408 Murine respirovirus Species 0.000 description 3
- 101150086694 SLC22A3 gene Proteins 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 3
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 229940094937 thioredoxin Drugs 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 102100021267 Anion exchange protein 4 Human genes 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 101150011616 Ctcf gene Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101100165087 Homo sapiens SLC4A9 gene Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 239000012580 N-2 Supplement Substances 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- KQNZDYYTLMIZCT-KFKPYADVSA-N (2e,7s,10e,12r,13r,15s)-12,15-dihydroxy-7-methyl-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\C2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KFKPYADVSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 1
- 108091008048 CMVpp65 Proteins 0.000 description 1
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010012253 E coli heat-labile enterotoxin Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 240000007839 Kleinhovia hospita Species 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710121478 Transcriptional repressor CTCF Proteins 0.000 description 1
- 101710128101 Transcriptional repressor CTCFL Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000003320 cell separation method Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000441 neoplastic stem cell Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
Definitions
- the present invention relates to a BORIS-derived tumor antigen peptide or the like useful as a preventive and / or therapeutic agent for cancer.
- cancer stem cells which are present in a small percentage of cancer cells, have high tumorigenicity, self-renewal ability, and differentiation ability, and are thought to be the causative cells involved in the development, recurrence, and metastasis of cancer. ing. Therefore, if cancer stem cells can be targeted, it is expected that cancer growth, recurrence and metastasis can be effectively suppressed. That is, the detection of cancer stem cells and the development of new therapeutic agents that target cancer stem cells are important issues for cancer medicine.
- cytotoxic T cells play an important role in the elimination of tumor cells and virus-infected cells by living bodies.
- the CTL recognizes a complex of an antigen peptide (tumor antigen peptide) on the tumor cell and a MHC (Major-Histocompatibility Complex) class I antigen (referred to as HLA class I antigen in humans).
- HLA class I antigen referred to as HLA class I antigen in humans.
- the tumor antigen peptide is produced by synthesizing a protein specifically expressed in tumor cells (tumor antigen protein) in the cell and then decomposing in the cell by a protease.
- the produced tumor antigen peptide binds to the MHC class I antigen (HLA class I antigen) in the endoplasmic reticulum to form a complex, and is carried to the cell surface to present the antigen.
- the tumor-specific CTL recognizes the complex containing the antigen peptide presented in this way, and exhibits an antitumor effect by attacking the tumor cell by cytotoxic action or production of lymphokine.
- the tumor antigen protein or tumor antigen peptide is used as a so-called cancer immunotherapeutic agent (cancer vaccine) to enhance cancer-specific CTL in the body of cancer patients. Treatments are being developed.
- BORIS (Brother of Regulator of Imprinted Sites) gene is a paralog of the CTCF gene and has 11 zinc finger regions between the two peptide coding regions of the N-terminal peptide region and the C-terminal peptide region. Yes. BORIS is known to function as a general transcription factor such as various gene expression repressors and activators, and is also known to be expressed in various tumor cells, particularly cancer stem cells. ing. In addition, the zinc finger region of BORIS has high homology with the CTCF gene, and there are 23 isoforms classified into 6 groups of subfamilies in BORIS, all of which occur after transcription. It has been reported that it is a splicing variant (Non-patent Document 1).
- BORIS is not expressed in normal tissues other than testis, it has been attracting attention as a target candidate for cancer diagnosis and treatment.
- Specific antibodies for each subfamily of BORIS, siRNA for inhibiting the expression of BORIS gene, etc. It has been reported (Patent Documents 1, 2, etc.).
- the sequence of the BORIS protein was analyzed, the sequence restricted by HLA-A0201 was predicted therefrom, and one of them was able to induce a CTL that specifically recognizes the antigen-presented cell. has also been reported (Non-Patent Document 2).
- An object of the present invention is to provide a tumor antigen peptide derived from BORIS, in particular, a tumor antigen peptide specific to an isoform or subfamily of BORIS, and a pharmaceutical composition useful for the prevention and / or treatment of cancer containing this as an active ingredient.
- a pharmaceutical composition for specifically treating cancer stem cells is provided.
- the present invention is specific to a specific subfamily of BORIS in cells exhibiting stem cell-like properties among cervical cancer and ovarian cancer.
- Further research based on this finding has shown that many cancer cells and / or cancer cells and / or cancer cells are induced by inducing cytotoxic T cells (CTLs) that recognize cells expressing a particular isoform or subfamily of BORIS.
- CTLs cytotoxic T cells
- the present invention relates to the following: [1] A method for inducing CTL that specifically recognizes a cell that expresses a BORIS gene belonging to isoform A or C, or subfamily 5 or 6, comprising the following (a) or (b): (A) a partial peptide of the BORIS protein, having a length of 8 to 20 amino acids and having an HLA binding ability, (B) a polynucleotide encoding at least one of the polypeptides described in (a) above, Any of the above, the method comprising contacting peripheral blood lymphocytes. [2] The method according to [1], which is performed in vitro.
- polypeptide of [3] or [4] which is a partial peptide of the polypeptide represented by SEQ ID NO: 2.
- polypeptide of [5] represented by SEQ ID NO: 10.
- the polypeptide of [9] represented by SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 or SEQ ID NO: 72.
- a cytotoxic T cell (CTL) inducer comprising at least one of the polypeptides of [3] to [14] as an active ingredient.
- a pharmaceutical composition comprising the CTL inducer of [16] as an active ingredient.
- a composition for preventing and / or treating cancer comprising the CTL inducer of [16] as an active ingredient.
- a composition for the prevention and / or treatment of cancer comprising cytotoxic T cells (CTL) induced by the method of [1] or [2] as an active ingredient.
- CTL cytotoxic T cells
- a pharmaceutical composition for treating or preventing cancer comprising as an active ingredient either the polynucleotide of [15] or the expression vector of [22].
- a method for inducing CTL that recognizes a specific isoform or subfamily BORIS, a tumor antigen peptide useful as an inducer of CTL used in the method, and prevention of cancer containing the same as an active ingredient and Pharmaceutical compositions useful for treatment are provided.
- some cancers express a specific subfamily BORIS in cells having stem cell-like properties (ie, cancer stem cells), so that they are selectively treated with the therapeutic agent of the present invention. It is also possible to do.
- FIG. 1 is a photograph of spheroids formed by a spheroid formation assay.
- FIG. 2 is a graph showing the relative expression levels of stem cell genes SOX2, NANOG, Oct3 / 4 in cervical cancer cell line CaSki and TCS cell line.
- FIG. 3 is a diagram showing the expression of BORIS in normal tissues.
- (A) shows the results of RT-PCR, and
- (b) is a graph showing the relative expression level.
- FIG. 4 is a graph showing the relative expression level of BORIS in bulk group cells and sphere group cells of various cervical cancer cell lines.
- FIG. 5 is a graph showing the relative expression level of BORIS in various cancer cells.
- FIG. 1 is a photograph of spheroids formed by a spheroid formation assay.
- FIG. 2 is a graph showing the relative expression levels of stem cell genes SOX2, NANOG, Oct3 / 4 in cervical cancer cell line CaSki and TCS cell line.
- FIG. 3 is a
- FIG. 6 is a diagram showing a comparison of expression levels of each BORIS subfamily between bulk group cells and sphere group cells in cervical cancer cell lines CaSki and MS751 cell lines.
- FIG. 7 is a diagram showing a comparison of expression levels of each BORIS subfamily between bulk group cells and sphere group cells in ovarian cancer cell lines TOV21G and smov2 cell lines.
- FIG. 8-1 is a photograph showing the result of a sphere formation assay when each BORIS subfamily is expressed in a large amount in a TCS cell line which is a cervical cancer cell line.
- FIG. 8-2 is a graph showing the results of a sphere formation assay when each BORIS subfamily is expressed in a large amount in a TCS cell line which is a cervical cancer cell line.
- FIG. 8-1 is a photograph showing the result of a sphere formation assay when each BORIS subfamily is expressed in a large amount in a TCS cell line which is a cervical cancer cell line.
- FIG. 8-2 is a graph
- FIG. 9-1 is a photograph showing the result of a sphere formation assay when each BORIS subfamily is expressed in a large amount in the SKG-IIIb cell line which is a cervical cancer cell line.
- FIG. 9-2 is a graph showing the results of a sphere formation assay when each BORIS subfamily is expressed in a large amount in the SKG-IIIb cell line which is a cervical cancer cell line.
- FIG. 10 is a graph showing the results of an HLA-A02 binding assay of HLA-binding peptide candidates extracted from a BORIS sf6-specific sequence.
- FIG. 11 is a graph showing the results of a folding test of HLA-A * 24: 02 binding BORIS-specific CTL epitope candidate peptides.
- FIG. 12-1 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A24-38 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the RMM peptide.
- FIG. 12-2 is a diagram showing the results of the second-stage analysis in which the sample collected from specimen number A24-38 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the RMM peptide. .
- FIG. 13 is a diagram showing the results of functional analysis of RMM peptide-specific CTL functions using RMM-Tet. It can be seen that IFN ⁇ is produced specifically for the RMM peptide when stimulated with the RMM peptide.
- FIG. 14-1 shows graphs comparing mRNA expression (a) and cell proliferation (b) in CaSki cell lines transfected with siRNA, respectively.
- FIG. 14-2 is a microscopic image of CaSki cells transfected with siRNA.
- FIG. 15 is a graph comparing stem cell gene expression of CaSki cell lines transfected with siRNA.
- FIG. 16-1 is a graph comparing the sphere-forming ability of the CaSki cell line (a) and MS751 cell line (b) transfected with siRNA.
- FIG. 16-2 is a microscopic image of each cell line transfected with siRNA.
- FIG. 17 shows a graph comparing the radiation resistance of cell lines transfected with siRNA.
- FIG. 18 is a Kaplan-Meier survival curve showing that the survival rate is markedly lowered when BORIS expression is high.
- FIG. 19-1 is a diagram showing a comparison of the expression levels of each BORIS subfamily between bulk group cells and sphere group cells in small cell lung cancer cell lines SBC1, SBC3, SBC5 and Lc817 cell lines.
- FIG. 19-2 is a diagram showing a comparison of the expression levels of each BORIS subfamily between bulk group cells and sphere group cells in non-small cell lung cancer cell lines Lu99A and 86-2 cell lines.
- FIG. 19-3 is a diagram showing a comparison of the expression levels of each BORIS subfamily of bulk group cells and sphere group cells in lung squamous cell carcinoma cell lines LK2, EBC1, and Sq1 cell lines.
- FIG. 19-4 is a diagram showing a comparison of the expression levels of each BORIS subfamily between the bulk group cells and the sphere group cells in the lung adenocarcinoma cell lines A549, LHK2, LHK2-SOX2 and PC3 cell lines.
- FIG. 19-5 is a diagram showing a comparison of the expression levels of each BORIS subfamily in the bulk group cells and the sphere group cells in primary adenocarcinoma lung cancer cells Primary3, Primary4, Primary5, and Primary7 cells.
- FIG. 20 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A2-34 is co-cultured with KLL peptide, and then the reaction with HLA-tetramer reagent is analyzed with a flow cytometer.
- FIG. 21 is a diagram showing the results of second-stage analysis in which a sample collected from specimen number A2-34 was co-cultured with KLL peptide, and then the reaction with HLA-tetramer reagent was analyzed with a flow cytometer.
- FIG. 22 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A2-29 was co-cultured with an LLF peptide, and then the reaction with the HLA-tetramer reagent was analyzed with a flow cytometer.
- FIGS. 23-1 and 2 are diagrams showing the results of the second stage analysis in which the sample collected from specimen number A2-29 was co-cultured with the LLF peptide, and then the reaction with the HLA-tetramer reagent was analyzed with a flow cytometer. It is.
- FIG. 24 is a diagram showing the results of analyzing a reaction with an HLA-tetramer reagent using a flow cytometer after co-culturing a sample collected from specimen number A2-S1 with LLF peptide-presenting cells.
- FIG. 25 is a diagram showing the results of ELISPOT analysis of CTL IFN ⁇ production ability induced by co-culture with LLF peptide-presenting cells from samples collected from specimen numbers A2-S1, A2-S2, and A2-S3. is there.
- FIG. 26 shows a sample obtained from Specimen No.
- FIG. 27 shows the results of analyzing the IFN ⁇ production ability by ELISPOT after single cloning and amplification of CTL induced from the sample collected from specimen number A2-S1 when cocultured with LLF peptide-presenting cells.
- FIG. 28 shows the results of analyzing the cytotoxic activity by LDH killing assay after monocloning and amplifying CTL derived from the sample collected from specimen number A2-S1 when co-cultured with LLF peptide-presenting cells.
- FIG. 29 is a diagram showing the results of analyzing a reaction with an HLA-tetramer reagent using a flow cytometer after co-culturing a sample collected from specimen number A24-S4 or specimen number A2-S5 with RMM peptide-presenting cells. is there.
- FIG. 30 is a diagram showing the results of ELISPOT analysis of the IFN ⁇ production ability of CTL induced when co-cultured with RMM peptide-presenting cells from samples collected from specimen number A24-S4 or specimen number A2-S5. .
- FIG. 31 shows a sample obtained from Specimen No. A24-S4.
- FIG. 32 shows a sample obtained from Specimen No. A2-S5. After monocloning and amplifying CTL induced when co-cultured with RMM peptide-presenting cells, the reaction with HLA-tetramer reagent was performed with a flow cytometer. It is a figure showing the result of having analyzed.
- FIG. 33 is a graph showing the results of a folding test of HLA-A * 02: 01-restricted, BORIS-specific CTL epitope candidate peptides.
- FIG. 34 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A2-29 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the VLE peptide.
- FIG. 35 is a diagram showing the results of a second-stage analysis in which a sample collected from specimen number A2-29 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the VLE peptide. Since CTL is detected in lane 10 in the first stage analysis, lane 10 is analyzed in the second stage analysis.
- FIG. 34 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A2-29 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the VLE peptide. Since CTL is detected in lane 10 in the first stage analysis, lane 10 is analyzed in
- FIG. 36 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A2-27 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the VLE peptide.
- FIG. 37 is a diagram showing the results of a second-stage analysis in which a sample collected from specimen number A2-27 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the VLE peptide. Since CTL is detected in lane 3 in the first stage analysis, lane 3 is analyzed in the second stage analysis.
- FIG. 38 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A2-34 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the VLE peptide.
- FIG. 39 is a diagram showing the results of a second-stage analysis in which a sample collected from specimen number A2-34 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the VLE peptide. Since CTL is detected in lane 4 in the first stage analysis, lane 4 is analyzed in the second stage analysis.
- FIG. 39 is a diagram showing the results of a second-stage analysis in which a sample collected from specimen number A2-34 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the VLE peptide. Since CTL is detected in lane 4 in the first stage analysis, lane 4 is analyzed in
- FIG. 40 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A2-29 was analyzed with a flow cytometer for the reaction with an HLA-tetramer reagent when co-cultured with a KLA peptide.
- FIG. 41 is a diagram showing the results of a second-stage analysis in which a sample collected from specimen number A2-29 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with KLA peptide. Since CTLs are detected in lanes 2, 5, and 11 in the first stage analysis, lanes 2, 5, and 11 are analyzed in the second stage analysis.
- FIG. 40 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A2-29 was analyzed with a flow cytometer for the reaction with an HLA-tetramer reagent when co-cultured with a KLA peptide.
- FIG. 42 is a diagram showing the results of a first-stage analysis in which a sample collected from specimen number A2-29 was analyzed with a flow cytometer for the reaction with an HLA-tetramer reagent when co-cultured with a VLT peptide.
- FIG. 43 is a diagram showing the results of a second-stage analysis in which a sample collected from specimen number A2-29 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the VLT peptide. Since CTLs are detected in lanes 7 and 9 in the first stage analysis, lanes 7 and 9 are analyzed in the second stage analysis.
- FIG. 44 is a diagram showing the results of functional analysis of KLA peptide-specific CTL functions using KLA-Tet. It can be seen that CD107a was detected specifically for the KLA peptide when stimulated with the KLA peptide.
- FIG. 45 is a diagram showing the results of functional analysis of VLT peptide-specific CTL functions using VLT-Tet. It can be seen that CD107a is induced specifically for the VLT peptide when stimulated with the VLT peptide.
- FIG. 46 is a graph showing the results of a folding test of HLA-A * 11: 01-restricted, BORIS-specific CTL epitope candidate peptides. The graph represents the peak area representing the HLA monomer.
- FIG. 47 shows the first stage of analyzing the reaction with the HLA-tetramer reagent when the sample collected from specimen number * 11-13 was co-cultured with SVL peptide, NTH peptide, KQL peptide, and GLI peptide using a flow cytometer. It is a figure showing the result of an analysis.
- FIG. 48 shows a second stage in which a sample taken from specimen number * 11-13 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with SVL peptide, NTH peptide, KQL peptide, and GLI peptide. It is a figure showing the result of an analysis.
- FIG. 49 shows the third stage in which the sample collected from specimen number * 11-13 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the SVL peptide, NTH peptide, KQL peptide, and GLI peptide. It is a figure showing the result of an analysis. Since CTL was detected in lane 1 and well B in the second stage analysis, lane 1 and well B are analyzed in the third stage analysis.
- FIG. 49 shows the third stage in which the sample collected from specimen number * 11-13 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with the SVL peptide, NTH peptide, KQL peptide, and GLI peptide. It is a figure showing the result of an analysis. Since CTL was detected in lane 1 and well B in the second stage analysis, lane 1 and well B are analyzed in the third stage analysis.
- FIG. 49 shows the third
- FIG. 50 shows a first stage in which a sample taken from specimen number * 11-13 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with SLA peptide, CSY peptide, TVY peptide, and TVL peptide. It is a figure showing the result of an analysis.
- FIG. 51 is a second-stage analysis in which the reaction with the HLA-tetramer reagent was analyzed with a flow cytometer when the sample collected from specimen number * 11-13 was co-cultured with SLA peptide, CSY peptide, TVY peptide, and TVL peptide. It is a figure showing the result of.
- FIG. 52 shows a third-stage analysis in which a sample taken from specimen number * 11-13 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with SLA peptide, CSY peptide, TVY peptide, and TVL peptide. It is a figure showing the result of. Since CTL was detected in lane 12 and well E in the second stage analysis, lane 12 and well E are analyzed in the third stage analysis.
- FIG. 52 shows a third-stage analysis in which a sample taken from specimen number * 11-13 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with SLA peptide, CSY peptide, TVY peptide, and TVL peptide. It is a figure showing the result of. Since CTL was detected in lane 12 and well E in the second stage analysis, lane 12 and well E are analyzed in the third stage analysis.
- FIG. 53 shows the first stage of analyzing the reaction with the HLA-tetramer reagent when a sample collected from specimen number * 11-16 was co-cultured with RMS peptide, GTM peptide, AAA peptide, and KLLF peptide using a flow cytometer. It is a figure showing the result of an analysis.
- FIG. 54 is a second-stage analysis in which a sample taken from specimen number * 11-16 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with RMS peptide, GTM peptide, AAA peptide, and KLLF peptide. It is a figure showing the result of.
- FIG. 55 is a third-stage analysis in which a sample taken from specimen number * 11-16 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with RMS peptide, GTM peptide, AAA peptide, and KLLF peptide. It is a figure showing the result of. Since CTL was detected in well E in lane 7 and well H in lane 11 in the second stage analysis, well E in lane 7 and well H in lane 11 are analyzed in the third stage analysis.
- FIG. 55 is a third-stage analysis in which a sample taken from specimen number * 11-16 was analyzed with a flow cytometer for the reaction with the HLA-tetramer reagent when co-cultured with RMS peptide, GTM peptide, AAA peptide, and KLLF peptide. It is a figure showing the result of. Since CTL was detected in well E in lane 7 and well H in lane 11 in the second stage analysis, well E in
- FIG. 56 shows the results of Western blotting using a 293T cell extract in which BORIS sf5 and BORIS sf6 with Myc Tag are transiently forcibly expressed. When using either specific antibody, the band was confirmed at the same position as when using the Myc Tag antibody, indicating the specificity of these antibodies.
- FIG. 57 shows the results of immunostaining of lung cancer tissue sections using a specific antibody of BORIS sf5. Even in the same lung cancer tissue, positive and negative BORIS sf5 expression was confirmed.
- (A) shows a negative stained image and
- (b) shows a positive stained image. In (b), cells stained brown are scattered, whereas in (a), they are rarely seen.
- epitope peptide means a polypeptide that is bound to MHC (HLA in humans) and presented as an antigen on the cell surface.
- the epitope peptide is an epitope peptide that is antigen-presented by binding to MHC class I and recognized by CD8-positive T cells, and CTL epitope peptide that is antigen-presented by binding to MHC class II and recognized by CD4-positive T cells.
- Helper epitope peptides which are epitope peptides to be processed.
- a polypeptide derived from a protein that is specifically or overexpressed in tumor cells is particularly referred to as a tumor antigen peptide.
- Antigen presentation refers to a phenomenon in which a polypeptide present in a cell binds to MHC and this MHC / antigen peptide complex is localized on the cell surface.
- the antigen presented on the cell surface is known to activate cellular immunity and humoral immunity after being recognized by T cells and the like.
- Tumor antigen peptides used for immunotherapy to activate sexual immunity and to be recognized by the T cell receptor of naive T cells and to induce naive T cells into CTLs having cytotoxic activity include MHC class Polypeptides that bind to I and are presented as antigens are preferred.
- antigen proteins taken up by antigen-presenting cells such as dendritic cells are recognized by CD4-positive T cells by binding to MHC class II and presented on the surface of the antigen-presenting cells.
- Helper T cells that activate sexual immunity and humoral immunity can be induced.
- Helper T cells not only have cytotoxic activity like CTL, but also play an important role in maintaining CTL activity and survival, so that tumor antigen peptides used in immunotherapy bind to MHC class II
- polypeptides that present antigens are also preferred. It is known that a polypeptide that binds to MHC class I is approximately 8 to 11 amino acids in length, and a polypeptide that binds to MHC class II is approximately 12 to 20 amino acids in length.
- tumor includes benign tumors and malignant tumors (cancer, malignant neoplasm).
- Cancer includes hematopoietic tumors, epithelial malignant tumors (cancer, carcinoma) and non-epithelial malignant tumors (sarcoma, sarcoma).
- BORIS simply means the Brother of Regulator of Imprinted Sites gene or its expression product, mRNA or protein. It is known that three types of promoters (referred to as promoter A, promoter B, and promoter C in order from the upstream promoter) are involved in the control of BORIS gene expression, and which promoter controls transcription? Are roughly divided into three isoforms (referred to as isoform A, isoform B and isoform C, respectively, corresponding to each promoter). Furthermore, each isoform is further classified into a plurality of splicing variants depending on how it is spliced during transcription.
- BORIS has 23 isoforms: 6 isoforms A (A1 to A6), 8 isoforms B (B0 to B7), and 9 isoforms C (C1 to C9). It has been known.
- the BORIS C1 isoform has the sequence represented by SEQ ID NO: 76.
- BORIS is a CTCF paralog also called 11-zinc finger protein
- BORIS protein has N-terminal peptide region and C-terminal peptide region on the N-terminal side and C-terminal side of 11 zinc finger regions, respectively. It has a structure. Depending on the isoform, the N-terminal peptide region is 24 amino acids, 53 amino acids and 258 amino acids in length, but sequences of the same length are highly conserved. There are various lengths of the C-terminal peptide region, and their sequences are also different. BORIS is classified into six subfamilies (subfamilies 1-6, sometimes simply abbreviated as sf1-6 in this specification) according to the sequence of such C-terminal peptide region. Therefore, the C-terminal sequence of each subfamily is a sequence unique to each subfamily, and is highly conserved among isoforms belonging to the same subfamily.
- the polypeptide of the present invention is antigen-presented on the cell surface of a cell expressing a specific isoform or subfamily BORIS, specifically isoform A or C, or BORIS belonging to subfamily 5 or 6. is there. Therefore, the polypeptide of the present invention is a BORIS partial peptide belonging to isoform A or C, or subfamily 5 or 6, which is 8 to 20 amino acids in length and has HLA binding ability. Many cancer cells including cancer stem cells express these BORIS, and therefore the polypeptide of the present invention is useful in cancer immunotherapy.
- the polypeptide of the present invention is a partial peptide of the polypeptide represented by SEQ ID NO: 1 which is a sequence unique to BORIS sf6 or SEQ ID NO: 2 which is a sequence unique to BORIS sf5, Peptides that bind to HLA, preferably MHC, particularly peptides that are presented with antigen by HLA, more preferably polypeptides that include MHC, particularly peptides that are presented with antigen by HLA and can induce CTL.
- SEQ ID NO: 1 which is a sequence unique to BORIS sf6 or SEQ ID NO: 2 which is a sequence unique to BORIS sf5
- Peptides that bind to HLA preferably MHC, particularly peptides that are presented with antigen by HLA, more preferably polypeptides that include MHC, particularly peptides that are presented with antigen by HLA and can induce CTL.
- the polypeptides of the present invention are preferably capable of binding to HLA class I, more preferably HLA-A24, HLA-A11 or HLA-A02, More preferably, it can bind to two or more of HLA-A02, HLA-A11 and HLA-A24. In another aspect, polypeptides capable of binding to HLA class II are also preferred.
- the polypeptide of the present invention may be subjected to processing such as processing before binding to MHC, and peptides that generate epitope peptides as a result of these treatments are also included in the polypeptide of the present invention.
- the target peptide or protein with HSP70, HSP90, or gp96, which are chaperones acting in the series of antigen presentation pathways.
- the polypeptide is fused to a chaperone that acts in the antigen presentation pathway.
- the epitope peptide of the present invention may be subjected to various modifications that can facilitate introduction into the living body.
- various modifications that can facilitate introduction into the living body include HIV PT (Protein Transduction) domain.
- the PT domain of HIV is a peptide composed of amino acids 49 to 57 of Tat protein.
- the target protein or peptide can be easily introduced into the cell.
- the amino acid length is not particularly limited as long as it is a sequence including the amino acid sequence of the epitope peptide.
- the polypeptide of the present invention itself is preferably an epitope peptide, and therefore the amino acid length is preferably about 8 to about 20 amino acids, more preferably about 8 to about 11 amino acids, and about 8 to about 10 amino acids. Further preferred.
- the polypeptide of the present invention is a partial peptide of the polypeptide represented by SEQ ID NO: 1, which is 8 to 11 amino acids in length and has HLA binding ability.
- the polypeptide of the present invention is a partial peptide of the polypeptide represented by SEQ ID NO: 2, which is 8 to 11 amino acids in length and has HLA binding ability.
- Whether or not a polypeptide has “HLA binding ability” can be easily examined using a method known in the art. Such methods include, but are not limited to, for example, the amount of HLA expressed on the cell surface (ie, HLA bound to a polypeptide using a monoclonal antibody against HLA, as described in WO2010 / 50190).
- HLA binding assay for observing the fluorescence intensity as a fluorescence intensity a binding assay using BIAcore surface plasmon resonance (SPR) described in Kim et al., Methods Mol Biol. 2013; 960: 447-59, Shin et al.
- iTopia iTopia Epitope Discovery System Assay, which is observed using an HLA antibody that specifically binds only when the HLA immobilized on the solid phase and the polypeptide are bound. Beckman coulter) is used.
- polypeptides represented by SEQ ID NO: 3 and SEQ ID NO: 4 as epitope peptide candidates, and sequences
- the polypeptide represented by number 10 was identified. Accordingly, in a more preferred embodiment, the polypeptide of the present invention is the polypeptide represented by SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 72. In another more preferred embodiment, the polypeptide of the present invention is the polypeptide represented by SEQ ID NO: 10.
- the polypeptide of the present invention is a partial peptide of BORIS belonging to isoform A or C, or subfamily 5 or 6, and has a binding ability to HLA-A11 antigen. Since the HLA-A11 antigen is an HLA belonging to HLA type I, the polypeptide of this embodiment preferably has a length of about 8 to about 11 amino acids.
- polypeptides represented by SEQ ID NOs: 60 to 73 were identified as epitope peptide candidates.
- high CTL inducing ability was confirmed in SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, and SEQ ID NO: 72.
- the polypeptide of the present invention is the polypeptide represented by SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 or SEQ ID NO: 72.
- the polypeptide represented by SEQ ID NO: 72 is more preferred because it is a partial polypeptide of the unique sequence of BORIS sf6 (SEQ ID NO: 1) as described above.
- the polypeptide of the present invention is a polypeptide represented by SEQ ID NO: 65, SEQ ID NO: 66 or SEQ ID NO: 67, which is a partial peptide of the polypeptide represented by SEQ ID NO: 76, In particular, it is also a peptide present in the zinc finger region.
- the zinc finger region of BORIS has high homology with CTCF that is known to be ubiquitously expressed in somatic cells, it has been considered difficult to obtain a BORIS-specific tumor antigen peptide. Therefore, it is surprising that the present inventors have now obtained a BORIS specific tumor antigen peptide derived from the zinc finger region.
- the polypeptide of the present invention is a partial peptide of BORIS belonging to isoform A or C, or subfamily 5 or 6, and has the ability to bind to HLA-A2 antigen and / or HLA-A24 antigen. It is polypeptide which has. Since the HLA-A2 antigen and the HLA-A24 antigen are HLA belonging to HLA type I, the polypeptide of this embodiment preferably has a length of about 8 to about 11 amino acids.
- polypeptides represented by SEQ ID NOs: 3 to 16 and 47 to 57 were identified as epitope peptide candidates.
- SEQ ID NO: 3 to 16 and 47 to 57 were identified as epitope peptide candidates.
- SEQ ID NO: 4 SEQ ID NO: 5
- SEQ ID NO: 10 SEQ ID NO: 47
- SEQ ID NO: 48 SEQ ID NO: 57
- SEQ ID NO: 57 may show suitable HLA binding ability. confirmed.
- the polypeptide of the present invention is the polypeptide represented by SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 47, SEQ ID NO: 48, and SEQ ID NO: 57.
- the polypeptides represented by SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5 are more preferred because they are partial polypeptides of the unique sequence of BORIS sf6 (SEQ ID NO: 1) as described above.
- polypeptide represented by SEQ ID NO: 10 is a partial polypeptide of the unique sequence of BORIS sf5 (SEQ ID NO: 2) as described above, and has the ability to bind to both HLA-A2 antigen and HLA-A24 antigen. More preferred.
- the polypeptide of the present invention is a polypeptide represented by SEQ ID NO: 47, SEQ ID NO: 48 and SEQ ID NO: 57, which are also partial peptides of the polypeptide represented by SEQ ID NO: 76. is there. Of these, the polypeptides represented by SEQ ID NO: 47 and SEQ ID NO: 57 are more preferred.
- polypeptides represented by SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 47, SEQ ID NO: 48, and SEQ ID NO: 57 are particularly preferred among these polypeptides represented by SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 47, SEQ ID NO: 48, and SEQ ID NO: 57. These polypeptides have been confirmed by the inventors' studies to be able to induce specific cytotoxic T cells (CTL).
- CTL cytotoxic T cells
- the polypeptide having the binding ability to the HLA-A2 antigen is not limited thereto, but is not limited thereto, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 47, and SEQ ID NO: 57. And the like.
- examples of the polypeptide having the ability to bind to the HLA-A24 antigen include, but are not limited to, the polypeptide represented by SEQ ID NO: 3 or SEQ ID NO: 10.
- the polypeptide of the present invention is a polypeptide in which one or more amino acids are added, deleted or substituted in the above polypeptide.
- the polypeptide of this embodiment is a polypeptide having one or more amino acids added, deleted, or substituted and still having HLA binding ability. It is known that a peptide having a binding property to an HLA antigen, particularly an HLA class I antigen, has a specific amino acid at a specific position, which is called an anchor motif. It is considered that the HLA binding ability is not lost even if the motif is replaced. Therefore, addition, deletion and substitution in the peptide of the present invention are preferably addition, deletion and substitution in which the anchor motif is replaced with another anchor motif.
- Ile, Met, Ser, Thr or Val is arranged at the second position from the N-terminus, and Lys or Arg is located at the ninth or tenth position. It is known that one of them is often arranged, and the preferable addition, deletion, and substitution described above are those in which Ile present at the second position from the N-terminus is replaced with Met, Ser, Thr or Val. Is mentioned.
- examples of preferable addition, deletion, and substitution of the present invention include (A) In the HLA-A11 antigen-binding peptide, the peptide at the second position from the N-terminus is Ile, Met, Ser, Thr or Val; (B) In the HLA-A11 antigen-binding peptide, the ninth or tenth peptide from the N-terminus is Lys or Arg; (C) In the HLA-A24 antigen-binding peptide, the peptide at the second position from the N-terminus is Trp, Phe, Met or Tyr; (D) In the HLA-A24 antigen-binding peptide, the ninth or tenth peptide from the N-terminus is Phe, Leu, Ile or Trp; (E) In the HLA-A2 antigen-binding peptide, the peptide at the second position from the N-terminus is Ile, Val, Ala or Thr; and / or (f) in the HLA-A2
- the synthesis of the polypeptide of the present invention can be performed according to a known method used in ordinary peptide chemistry. Such known methods include literature (Peptide Synthesis, Interscience, New York, 1966; The Proteins, Vol 2, Academic Press Inc., New York, 1976; Peptide Synthesis, Maruzen Co., 1975; Fundamentals and Experiments of Peptide Synthesis. , Maruzen Co., Ltd., 1985; Development of pharmaceuticals continued Volume 14: Peptide synthesis, Hirokawa Shoten, 1991, which are incorporated herein by reference).
- the polypeptide of the present invention can be used in vivo by subjecting it to a CTL induction method described later, an assay using a human model animal (WO02 / 47474, Int J. Cancer: 100,565-570 (2002)) or the like. The activity can be confirmed.
- the polypeptide of the present invention contains these as described in the present specification. Can be used to induce cytotoxic T cells (CTLs) that specifically recognize these cells. Therefore, the polypeptide of the present invention is useful for prevention and / or treatment of cancer, and can be used as an active ingredient of a pharmaceutical composition.
- CTLs cytotoxic T cells
- the present invention derived from an amino acid sequence unique to such a subfamily. This polypeptide can be particularly preferably used in a pharmaceutical composition for treating cancer stem cells.
- the polypeptide of the present invention may be for preventing and / or treating cancer.
- the present invention also relates to the use of the polypeptide of the present invention for the manufacture of a medicament for the prevention and / or treatment of cancer.
- the polynucleotide of the present invention includes a polynucleotide encoding at least one polypeptide of the present invention.
- the polynucleotide of the present invention may be any of cDNA, mRNA, cRNA, or synthetic DNA. Further, it may be either single-stranded or double-stranded.
- SEQ ID NO: 3 SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 10, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 57, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67 or SEQ ID NO: 72
- examples thereof include a polynucleotide comprising a nucleotide sequence encoding the nucleotide sequence encoding the described amino acid sequence so that each polynucleotide can be expressed.
- the polynucleotide of the present invention is used to produce the polypeptide of the present invention in a host using a gene recombination technique. In this case, since the frequency of use of amino acid codons differs between hosts, the codons of amino acids may be changed to match the frequency of use of the host to be produced.
- the polynucleotide of the present invention can take either a single-stranded or double-stranded form.
- a recombinant expression vector for expressing the polypeptide of the present invention can be prepared by inserting the polynucleotide of the present invention into an expression vector. That is, the category of the polynucleotide of the present invention includes a recombinant expression vector prepared by inserting the double-stranded polynucleotide of the present invention into an expression vector.
- the polynucleotide of the present invention is useful for prevention and / or treatment of cancer, and can be used as an active ingredient of a pharmaceutical composition.
- the polynucleotide of the present invention may be for preventing and / or treating cancer.
- the present invention also relates to the use of the polynucleotide of the present invention for the manufacture of a medicament for the prevention and / or treatment of cancer.
- expression vectors can be used depending on the host used, the purpose, and the like, and those skilled in the art can appropriately select them.
- expression vectors that can be used in the present invention include plasmids, phage vectors, virus vectors, cosmid vectors, fosmid vectors, artificial chromosome vectors (HAC, YAC, BAC, PAC) and the like.
- HAC chromosome vector
- examples of vectors include plasmid vectors such as pUC118, pUC119, pBR322, pCR3, and pGATA, and phage vectors such as ⁇ ZAPII and ⁇ gt11.
- examples of the vector include pYES2, pYEUra3, and pYAC4.
- examples include pAcSGHisNT-A, pIEx, and pBAC.
- plasmid vectors such as pCEP4, pKCR, pCDM8, pGL2, pcDNA3.1, pRc / RSV, pRc / CMV, retrovirus vectors, adenovirus vectors, adeno-associated virus vectors, vaccinia vectors, Examples thereof include virus vectors such as Sendai virus vector and lentivirus vector.
- the vector may appropriately have factors such as a promoter capable of inducing expression, a gene encoding a signal sequence, a marker gene for selection, and a terminator. Further, a sequence expressed as a fusion protein with thioredoxin, His tag, GST (glutathione S-transferase) or the like may be added so that isolation and purification can be facilitated.
- a GST fusion protein vector such as pGEX4T
- an appropriate promoter such as lac, tac, trc, trp, CMV, SV40 early promoter
- a vector having a tag sequence such as Myc, His, etc.
- pcDNA3.1 / Myc-His a vector having a tag sequence such as Myc, His, etc.
- pET32a that expresses a fusion protein with thioredoxin and His tag can be used.
- a transformed cell containing the expression vector By transforming the host with the expression vector prepared above, a transformed cell containing the expression vector can be prepared.
- any cell may be used as long as the function of the polypeptide of the present invention is not impaired, and examples thereof include bacteria such as Escherichia coli and attenuated Salmonella, yeast, insect cells, and animal cells.
- E. coli include HB101 strain, C600 strain, JM109 strain, DH5 ⁇ strain, AD494 (DE3) strain, BL21 strain of E. coli K-12 strain.
- yeast include Saccharomyces cerevisiae.
- animal cells include L929 cells, BALB / c3T3 cells, C127 cells, CHO cells, COS cells, Vero cells, HeLa cells, and 293-EBNA cells.
- Insect cells include sf9, Hi5, S2, and the like.
- a normal method suitable for the host cell may be used. Specific examples include a calcium phosphate method, a DEAE-dextran method, an electroporation method, a method using a lipid for gene transfer (Lipofectamine, Lipofectin; Gibco-BRL) (lipofection method), and the like.
- a transformed cell in which the expression vector is introduced into the host cell can be selected by culturing in a normal medium containing a selection marker.
- the polypeptide of the present invention can be produced by continuing to culture the transformed cells obtained as described above under suitable conditions.
- the obtained polypeptide can be further isolated and purified by general biochemical purification means.
- the purification means include salting out, ion exchange chromatography, adsorption chromatography, affinity chromatography, gel filtration chromatography and the like.
- the polypeptide of the present invention when expressed as a fusion protein with the aforementioned thioredoxin, His tag, GST or the like, it can be isolated and purified by a purification method utilizing the properties of these fusion protein and tag.
- the polynucleotide encoding the polypeptide of the present invention may be in the form of DNA or RNA. These polynucleotides of the present invention can be easily produced using conventional methods known in the art based on the amino acid sequence information of the polypeptide of the present invention and the sequence information of the DNA encoded thereby. . Specifically, it can be produced by ordinary DNA synthesis or PCR amplification.
- the polynucleotide encoding the polypeptide of the present invention includes the polynucleotide encoding the epitope peptide.
- CTL inducer comprising the polypeptide of the present invention as an active ingredient
- the polypeptide of the present invention can be used in a method for inducing CTLs against cancer cells, so that it can be used as a tumor antigen peptide. It can be a CTL inducer. That is, by isolating peripheral blood lymphocytes from a human blood sample and adding and stimulating the polypeptide of the present invention in vitro, CTLs that specifically recognize HLA antigen-positive cells pulsed with the peptide are induced. (J. Immunol., 154, p2257, 1995).
- CTL the presence or absence of induction of CTL can be confirmed, for example, by measuring the amount of various cytokines (for example, IFN ⁇ ) produced by CTL in response to antigen peptide-presenting cells by, for example, ELISA.
- the method for measuring the cytotoxicity of CTL against antigen peptide-presenting cells labeled with 51 Cr (51 Cr release assay, Int.J.Cancer, 58: p317,1994) can be confirmed by.
- CTL clones can also be established by the method described in Int. J. Cancer, 39, 390-396, 1987, N. Eng. J. Med, 333, 1038-1044, 1995, and the like.
- the CTL induced by the polypeptide of the present invention has a toxic effect on cells presenting the polypeptide of the present invention as an antigen and the ability to produce lymphokines. Since the polypeptide of the present invention is a tumor antigen peptide as described above, it can exert an antitumor action, preferably an anticancer action, through these functions. Therefore, the polypeptide of the present invention and the CTL derived thereby can be used as an active ingredient of a medicament or pharmaceutical composition for preventing and / or treating cancer.
- the polypeptide of the present invention When a CTL inducer containing the polypeptide of the present invention as an active ingredient is administered to a cancer patient, the polypeptide of the present invention is presented on the HLA antigen of the antigen-presenting cell, and the binding complex between the HLA antigen and the presented peptide Specific CTLs can proliferate and destroy cancer cells, so that cancer can be prevented and / or treated. Therefore, the CTL inducer comprising the polypeptide of the present invention as an active ingredient can be preferably used for subjects positive for HLA-A02 antigen, HLA-A11 antigen and / or HLA-A24 antigen.
- a subject suffering from a cancer that expresses BORIS belonging to isoform A or C, or subfamily 5 or 6, more preferably suffering from a BORIS sf5 and / or sf6 positive cancer can be used for subjects.
- BORIS positive cancer belonging to isoform A or C or subfamily 5 or 6 include cancers (tumors) such as cervical cancer, ovarian cancer, uterine cancer, breast cancer, colon cancer, lung cancer, melanoma, etc.
- the CTL inducer of the present invention can be used for the prevention and / or treatment of these cancers. In particular, it can be preferably used for the prevention and / or treatment of cancer in organs unique to women such as cervical cancer, ovarian cancer, uterine cancer, and lung cancer.
- prevention of cancer includes not only prevention of cancer in patients but also cancer treatment such as prevention of recurrence, surgery, radiation therapy or drug therapy in patients whose primary tumor has been removed by surgery. This includes prevention of metastasis of tumors that could not be completely removed.
- cancer treatment includes not only cancer healing and symptom improvement that reduce cancer, but also progression that suppresses cancer cell growth, tumor expansion, or cancer cell metastasis from the primary lesion. Prevention etc. are included.
- the CTL inducer comprising the polypeptide of the present invention as an active ingredient suffers from BORIS positive, preferably BORIS sf5 and / or sf6 positive cancer belonging to isoform A or C, or subfamily 5 or 6. This is particularly effective for HLA-A02, HLA-A11 or HLA-A24 positive cancer patients. Specifically, for example, it can be used for the prevention or treatment of cancers (tumors) such as cervical cancer, ovarian cancer, uterine cancer, breast cancer, colon cancer, lung cancer and melanoma. In particular, it can be preferably used for the prevention and / or treatment of cancer in organs peculiar to women such as cervical cancer, ovarian cancer and uterine cancer.
- the dosage form of the CTL inducer comprising the polypeptide of the present invention as an active ingredient is not particularly limited. Particulate preparations, preparations combined with lipids, microsphere preparations, microcapsule preparations and the like.
- the CTL inducer comprising the polypeptide of the present invention as an active ingredient is administered in combination with a pharmaceutically acceptable carrier, for example, an appropriate adjuvant, or in combination so that cellular immunity is effectively established. be able to.
- a pharmaceutically acceptable carrier for example, an appropriate adjuvant, or in combination so that cellular immunity is effectively established. be able to.
- adjuvants known in the art can be applied.
- CpG monophosphoryl lipid A (monophosphoryl lipid A) as cell types, such as aluminum hydroxide, aluminum phosphate, and calcium phosphate as gel types.
- Lipid A Lipid A
- cholera toxin Escherichia coli heat-labile toxin
- pertussis toxin and Muramyl dipeptide (MDP), etc.
- Freund's incomplete adjuvant MF59 and SAF
- Immunostimulatory complexes ISCOMs
- nanoparticle types such as liposomes, biodegradable microspheres, and QS-21 derived from saponins, such as nonionic block copolymers, muramylpe
- cytokine types such as peptide analogs (Muramyl® peptide analog), polyphosphazenes, and synthetic polynucleotides include IFN- ⁇ , IFN- ⁇ , IFN ⁇ , IL-2, and IL-12.
- the administration method examples include any known administration method such as intradermal administration, subcutaneous administration, intramuscular administration, and intravenous administration.
- the dosage of the polypeptide of the present invention in the preparation can be appropriately adjusted depending on the disease to be treated, the age, weight, etc. of the patient, but is usually 0.0001 mg to 1000 mg, preferably 0.001 mg to 1000 mg, more preferably. Is 0.1 mg to 10 mg, which is preferably administered once every few days to several months.
- a CTL inducer containing the polypeptide of the present invention as an active ingredient it is possible to effectively treat BORIS positive cancer belonging to isoform A or C, or subfamily 5 or 6. Is possible. Therefore, in one aspect, the present invention includes a pharmaceutical composition containing the CTL inducer as an active ingredient, preferably a composition for treating cancer stem cells, or a composition for preventing and / or treating cancer.
- CTL inducer comprising the polynucleotide of the present invention as an active ingredient
- the cell expressing the polynucleotide of the present invention becomes a cell that presents the polypeptide of the present invention as an antigen. It is characterized by being recognized by T cells. Therefore, the polynucleotide of the present invention can also be an inducer of CTL.
- the induced CTL can exert an antitumor action, preferably an anticancer action, through a cytotoxic action or lymphokine production, like the CTL induced by the polypeptide of the present invention. Therefore, the polynucleotide of the present invention can be used as an active ingredient of a medicine or pharmaceutical composition for treating or preventing cancer.
- the inducer of CTL containing the polynucleotide of the present invention as an active ingredient is capable of treating and / or preventing cancer by, for example, administering and expressing the polynucleotide of the present invention to a cancer patient.
- a tumor antigen peptide is highly expressed in antigen-presenting cells. Thereafter, the resulting tumor antigen peptide binds to HLA-A02 antigen, HLA-A11 antigen, HLA-A24 antigen or the like to form a complex, and the complex is presented at a high density on the surface of the antigen-presenting cell.
- Cancer-specific CTL grows efficiently in the body and destroys cancer cells. As described above, treatment or prevention of cancer is achieved.
- the CTL inducer comprising the polynucleotide of the present invention as an active ingredient can be preferably used for subjects positive for HLA-A02 antigen, HLA-A11 antigen and / or HLA-A24 antigen.
- a subject suffering from a cancer expressing BORIS belonging to isoform A or C or subfamily 5 or 6, more preferably a subject suffering from a BORIS sf5 and / or sf6 positive cancer Can be used against.
- Examples of BORIS positive cancer belonging to isoform A or C or subfamily 5 or 6 include cancers (tumors) such as cervical cancer, ovarian cancer, uterine cancer, breast cancer, colon cancer, lung cancer, melanoma, etc.
- the CTL inducer of the present invention can be used for the prevention or treatment of these cancers.
- it can be preferably used for the prevention and / or treatment of cancer in organs unique to women such as cervical cancer, ovarian cancer, uterine cancer, and lung cancer.
- Examples of the method using a viral vector include DNA viruses or RNA viruses such as retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, vaccinia viruses, Sendai viruses, lentiviruses, poxviruses, polioviruses, and synbisviruses.
- DNA viruses or RNA viruses such as retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, vaccinia viruses, Sendai viruses, lentiviruses, poxviruses, polioviruses, and synbisviruses.
- retroviruses adenoviruses, adeno-associated viruses, vaccinia viruses and the like are particularly preferred.
- Examples of other methods include a method in which an expression plasmid is directly administered into muscle (DNA vaccine method), a liposome method, a lipofectin method, a microinjection method, a calcium phosphate method, an electroporation method, and the like. The method is preferred.
- a bacterial vector method in which an expression plasmid is introduced into attenuated bacteria such as Salmonella and the bacteria are administered to express the polypeptide of the present invention can also be used.
- the polynucleotide of the present invention When administering the polynucleotide of the present invention, it is possible to appropriately select and administer an appropriate administration route and administration form according to the disease or symptom to be treated. For example, it can be administered in a form that can be injected into a vein, artery, subcutaneous, intradermal, intramuscular or the like. In the case of administration, for example, it can be in the form of a preparation such as a liquid, but is generally an injection containing the polynucleotide of the present invention which is an active ingredient, and if necessary, a pharmaceutically acceptable carrier. (Carrier) may be added.
- Carrier may be added.
- the liposome or membrane-fused liposome (Sendai virus (HVJ) -liposome etc.) containing the polynucleotide of the present invention may be in the form of a liposome preparation such as a suspension, a freezing agent, or a centrifugal concentrated freezing agent. it can.
- the content of the polynucleotide of the present invention in the preparation can be appropriately adjusted depending on the disease to be treated, the age, weight, etc. of the patient.
- the content of the polynucleotide is 0.0001 mg to 100 mg, preferably 0. 001 mg to 10 mg of the polynucleotide of the present invention can be administered once every several days to several months.
- a person skilled in the art can appropriately select suitable cells, vectors, administration methods, dosage forms, and dosages.
- Antigen-presenting cell of the present invention The polypeptide or polynucleotide of the present invention described above can be used in vitro as follows, for example, in the treatment of cancer patients. That is, antigen-presenting cells can be prepared by bringing either the polypeptide or polynucleotide of the present invention into contact with cells having antigen-presenting ability. The production of antigen-presenting cells may be performed in vitro or in vivo, but is preferably performed in vitro. Specifically, the present invention relates to an isolated antigen-presenting cell derived from a cancer patient and any of the polypeptides or polynucleotides of the present invention, preferably by contacting them in vitro.
- the antigen-presenting cell of the present invention includes, for example, (1) an epitope peptide pulse antigen-presenting cell in which an antigen-presenting cell and a CTL epitope peptide are mixed for 30 minutes to 1 hour in an appropriate culture medium, and (2) a CTL epitope peptide is encoded.
- Examples include cells in which a CTL epitope peptide is presented to antigen-presenting cells by gene transfer or the like using a nucleic acid, and (3) artificially-produced artificial antigen-presenting cells having antigen-presenting ability.
- cell having antigen-presenting ability expresses MHC capable of presenting the polypeptide of the present invention, preferably HLA-A02 antigen, HLA-A11 antigen and / or HLA-A24 antigen on the cell surface.
- MHC capable of presenting the polypeptide of the present invention
- HLA-A02 antigen, HLA-A11 antigen and / or HLA-A24 antigen on the cell surface.
- a professional antigen presentation cell is preferable and the dendritic cell which is especially considered to be high in antigen presentation ability is more preferable.
- Artificial antigen-presenting cells with antigen-presenting ability that are artificially prepared are prepared by immobilizing a ternary complex of HLA, CTL epitope peptide, and ⁇ 2-microglobulin on beads such as a lipid bilayer membrane, plastic, or latex.
- costimulatory molecule such as CD80, CD83, or CD86 that can stimulate the tumor, or by fixing an antibody that acts agonistically on CD28, which is a ligand on the T cell side that binds to the costimulatory molecule It can be produced.
- the substance added to prepare the antigen-presenting cell of the present invention from the cells having the antigen-presenting ability may be either the polypeptide or the polynucleotide of the present invention.
- the antigen-presenting cell of the present invention is obtained by, for example, isolating a cell having an antigen-presenting ability from a cancer patient, and pulsing the cell with the polypeptide of the present invention in vitro to produce HLA-A02 antigen, It can be obtained by presenting a complex of the HLA-A24 antigen and the polypeptide of the present invention.
- the antigen-presenting cells of the present invention can be prepared by inducing dendritic cells, culturing the dendritic cells with the polypeptide of the present invention, and pulsing them.
- the antigen-presenting cell of the present invention is prepared by introducing the polynucleotide of the present invention into a cell having the antigen-presenting ability, the polynucleotide may be in the form of RNA, even in the form of DNA. May be. Methods for producing antigen-presenting cells by introducing polynucleotides are known in the art and can be appropriately selected by those skilled in the art.
- the antigen-presenting cell can be an active ingredient of a CTL inducer.
- the CTL inducer containing the antigen-presenting cells as an active ingredient preferably contains physiological saline, phosphate buffered saline (PBS), a medium, or the like in order to stably maintain the antigen-presenting cells.
- the administration method include intravenous administration, subcutaneous administration, and intradermal administration.
- a CTL inducer containing such antigen-presenting cells as an active ingredient is returned to the patient's body, thereby suffering from a BORIS-positive cancer belonging to isoform A or C, or subfamily 5 or 6.
- CTLs specific to cancer cells presenting the polypeptide of the present invention as an antigen are efficiently induced in the body of a patient, and as a result, isoform A or C presenting the polypeptide of the present invention as an antigen, or subfamily 5
- a BORIS positive cancer belonging to 6 can be treated.
- Cytotoxic T cell (CTL) of the present invention The polypeptides and polynucleotides of the present invention can be used as follows in the treatment of cancer patients. That is, by contacting any of the polypeptides and polynucleotides of the present invention with peripheral blood lymphocytes, cells expressing a CTL, particularly isoform A or C, or a BORIS gene belonging to subfamily 5 or 6 are specifically expressed. Recognizing CTL can be induced. That is, the present invention provides a CTL induced by bringing a peripheral blood lymphocyte derived from a cancer patient into contact with either the polypeptide or polynucleotide of the present invention, and a method for inducing the CTL.
- Such a method may be performed in vitro or in vivo, but is preferably performed in vitro.
- Specific examples of the method for inducing CTLs of the present invention include the following methods. First, PBMC or T cells are stimulated directly with the polypeptide of the present invention, or stimulated with antigen-presenting cells pulsed with the peptide, antigen-introduced cells into which genes are introduced, or artificial antigen-presenting cells having an antigen-presenting ability prepared artificially To do. CTLs induced by stimulation are cultured for 7-10 days at 37 ° C. in a 5% CO 2 thermostat. By repeating the stimulation with CTL epitope peptide and IL-2 or antigen-presenting cell and IL-2 once a week, the necessary number of CTLs is secured.
- melanoma a therapeutic effect is observed in adoptive immunotherapy in which a patient's own tumor-infiltrating T cells are cultured in large quantities outside the body and returned to the patient.
- splenocytes were stimulated in vitro with tumor antigen peptide TRP-2, CTL specific for the tumor antigen peptide was propagated, and the CTL was administered to melanoma transplanted mice to suppress metastasis. Is allowed. This is based on the result of in vitro proliferation of CTL that specifically recognizes a complex of MHC of an antigen-presenting cell and a tumor antigen peptide.
- a therapeutic method in which a patient's peripheral blood lymphocytes are stimulated in vitro using the polypeptide or polynucleotide of the present invention to increase tumor-specific CTL, and then this CTL is returned to the patient is useful.
- the CTL can be used as an active ingredient of a therapeutic or prophylactic agent for cancer.
- the therapeutic agent or prophylactic agent preferably contains physiological saline, phosphate buffered saline (PBS), a medium, or the like in order to stably maintain CTL.
- the administration method include intravenous administration, subcutaneous administration, and intradermal administration.
- a BORIS-positive cancer belonging to isoform A or C of the present invention or subfamily 5 or 6 by returning a cancer therapeutic or prophylactic agent containing such CTL as an active ingredient to the body of the patient.
- Cancer cells can be treated by damaging cancer cells by damaging the cancer cells in the body affected by CTL.
- HLA-multimer of the present invention is a tetramer obtained by biotinylating a complex (HLA-monomer) in which HLA and ⁇ 2 microglobulin are associated with a peptide (antigen peptide) and binding it to avidin.
- HLA-monomer a complex obtained by biotinylating a complex in which HLA and ⁇ 2 microglobulin are associated with a peptide (antigen peptide) and binding it to avidin.
- HLA-tetramers containing various antigen peptides have been prepared, and HLA-tetramers containing the polypeptide of the present invention and HLA-A02, HLA-A11 or HLA-A24 can be easily prepared.
- HLA-dimer and HLA-pentamer are also based on the same principle, in which the HLA monomer is dimerized and pentamerized, respectively.
- polypeptide of the present invention that is, isoform A or C, or a partial peptide having BOLA HLA binding ability, particularly HLA class I binding ability belonging to subfamily 5 or 6, and HLA-A02, HLA-A11 or HLA HLA monomers and HLA multimers, particularly HLA-tetramers, containing -A24 are also an aspect of the present invention.
- an HLA-tetramer containing the polypeptide of the present invention and HLA-A02, HLA-A11 or HLA-A24 can be mentioned.
- the HLA-tetramer is preferably fluorescently labeled so that CTLs bound by known detection means such as flow cytometry and fluorescence microscope can be easily selected or detected.
- detection means such as flow cytometry and fluorescence microscope can be easily selected or detected.
- Specific examples include HLA-tetramers labeled with phycoerythrin (PE), fluorescein isothiocyanate (FITC), peridinin chlorophyll protein (PerCP) and the like.
- HLA-tetramer examples include US Patent No. 5,635,363, French Patent Application No. FR9911133, Science 279: 2103-2106 (1998), Science 274: 94-96 (1996), etc. Those described in the literature are listed, and those skilled in the art can select an appropriate method.
- An example of production will be briefly described as follows. First, HLA-A24, HLA-A11 or HLA-A02 expression vector and ⁇ 2 microglobulin expression vector are introduced into E. coli or mammalian cells capable of expressing the protein and expressed. Here, it is preferable to use E. coli (for example, BL21).
- the obtained monomer HLA-A24, HLA-A11 or HLA-A02 complex is mixed with the polypeptide of the present invention to form a soluble HLA-peptide complex.
- the sequence of the C-terminal site of HLA-A02, HLA-A11 or HLA-A24 in the HLA-peptide complex is biotinylated with a BirA enzyme.
- An HLA-tetramer can be prepared by mixing the biotinylated HLA-peptide complex and the fluorescently labeled avidin at a molar ratio of 4: 1. In each step, protein purification by gel filtration or the like is preferably performed.
- the tumor-specific CTL of the present invention can be detected and purified.
- the method for generating CTL include the following methods. (I) reacting PBMC with an appropriate concentration of the HLA-tetramer of the present invention. Since the CTL bound to the HLA-tetramer of the present invention is stained with a labeling dye, only the CTL stained with a cell sorter, a microscope or the like is isolated.
- the CTL isolated in this way is stimulated and proliferated with T cell stimulating agents such as anti-CD3 antibody, PHA and IL-2, and antigen-presenting cells whose proliferation ability has been lost by X-ray irradiation or mitomycin treatment, Ensure the required number of cells.
- T cell stimulating agents such as anti-CD3 antibody, PHA and IL-2, and antigen-presenting cells whose proliferation ability has been lost by X-ray irradiation or mitomycin treatment, Ensure the required number of cells.
- T cell stimulating agents such as anti-CD3 antibody, PHA and IL-2, and antigen-presenting cells whose proliferation ability has been lost by X-ray irradiation or mitomycin treatment, Ensure the required number of cells.
- the HLA-monomer and / or tetramer of the present invention is immobilized on a sterile plate and the PBMC is cultured on the immobilized plate. In order to isolate the CTL bound to the HLA-monomer and /
- T-cell stimulating drugs such as anti-CD3 antibody, PHA, IL-2, and antigen-presenting cells whose proliferation ability has been lost by treatment with X irradiation or mitomycin.
- T-cell stimulating drugs such as anti-CD3 antibody, PHA, IL-2, and antigen-presenting cells whose proliferation ability has been lost by treatment with X irradiation or mitomycin.
- CD28 acts agonistically on the HLA-monomer and / or tetramer of the present invention and CD28, which is a costimulatory molecule such as CD80, CD83, CD86, or a T cell side ligand that binds to the costimulatory molecule.
- the antibody to be immobilized is immobilized on a sterile plate or the like, and PBMC is cultured on the immobilized plate.
- IL-2 is added to the medium and cultured in a 5% CO 2 constant temperature bath at 37 ° C. for 7 to 10 days.
- the cultured cells are collected and cultured on a new solid phase plate. By repeating this operation, the required number of CTLs are secured.
- the differentiation stage of CTL can be examined (SederedRA, Ahmed R., Nat Immunol., 2003; 4: 835-842) .
- it can be used for functional evaluation of CTL by combining with intracellular cytokine staining method. Therefore, if a CTL epitope peptide is identified and an HLA-tetramer is prepared, quantification and qualification of the CTL induced against the epitope peptide becomes possible, and diagnostic information for a disease associated with the protein from which the epitope peptide is derived can be obtained. A great contribution can be made in obtaining.
- Tumor detection method (examination method, diagnosis method)
- the present invention also provides a tumor detection method (examination method, diagnostic method) using the above-described HLA-tetramer of the present invention.
- the detection method (diagnostic method) of the present invention using the HLA-tetramer of the present invention typically involves collecting blood from a subject or collecting a part of a test tissue suspected of having a tumor with a biopsy or the like.
- the amount of CTL that recognizes a complex between an HLA antigen and a BORIS-derived tumor antigen peptide belonging to isoform A or C, or subfamily 5 or 6 contained in the HLA-tetramer of the present invention is detected and measured Whether or not there is morbidity of isoform A or C such as cervical cancer, ovarian cancer, uterine cancer, breast cancer, colon cancer, lung cancer, melanoma, or BORIS positive cancer (tumor) belonging to subfamily 5 or 6
- the degree is detected, examined or diagnosed. In particular, it is possible to detect, test or diagnose the presence or absence of cancer in a female-specific organ, such as cervical cancer, ovarian cancer, uterine cancer, or lung cancer.
- CTL specific for BORIS, particularly isoform A or C, or BORIS belonging to subfamily 5 or 6 in a biological sample collected from a subject can be quantified.
- the quantification can be performed, for example, as follows. Peripheral blood or PBMC collected from the subject is reacted with an appropriate concentration of HLA-tetramer. Since CTL bound to HLA-tetramer is stained with a labeling dye, it is counted using a flow cytometer, a microscope or the like.
- BORIS-specific CTL T cell subsets can be determined simultaneously by reacting with anti-CD3 antibody, anti-CD4 antibody, anti-CD8 antibody, etc. labeled with a different dye from HLA-tetramer reagent it can.
- the detection (test, diagnosis) method of the present invention detects (examines, diagnoses) whether or not the tumor has improved, for example, when a therapeutic agent is administered to improve the tumor in a patient having a tumor.
- the detection (test, diagnosis) method of the present invention is useful for selection of cancer patients to whom a drug containing the polypeptide or polynucleotide of the present invention as an active ingredient can be effectively applied, and for predicting or determining the therapeutic effect of the drug. Can also be used.
- a specific embodiment of the detection (testing) method of the present invention using the HLA-tetramer of the present invention comprises the following steps (a) and (b), and optionally (c): (A) contacting the biological sample obtained from the subject with the HLA-tetramer of the present invention, (B) a step of measuring the amount of CTL recognizing a complex of a BORIS sf5 or sf6-derived tumor antigen peptide and HLA antigen in the biological sample, using the amount of cells bound to the HLA-tetramer as an index, (C) A step of determining the onset of cancer based on the result of (b).
- a specific embodiment of the diagnostic method of the present invention using the HLA-tetramer of the present invention includes the steps (a), (b) and (c) described above.
- One aspect of the detection method (test method, diagnostic method) of the present invention using the HLA-tetramer of the present invention is carried out by detecting the polypeptide-specific CTL of the present invention in a biological sample and measuring the amount thereof.
- the HLA-tetramer of the present invention can be prepared and used to quantify antigen peptide-specific CTLs in peripheral blood lymphocytes of patients suspected of cancer using a flow cytometer.
- Prediction, determination, judgment, or diagnosis of the presence or absence of a tumor is, for example, the amount of a polypeptide-specific CTL of the present invention in a subject's blood or a test tissue suspected of having a tumor, or the amount of cells presenting the polypeptide of the present invention.
- the BORIS gene or isoform A or C in a normal corresponding tissue, or the BORIS mRNA expression level belonging to subfamily 5 or 6 or the polypeptide level or CTL level of the present invention is used as a reference value. This can be done by comparing the reference value with the level in the sample obtained from the subject and determining the difference between the two.
- the comparison of the level between the test tissue of the subject and the normal corresponding tissue can be performed by performing measurements on the test subject biological sample and the normal subject biological sample in parallel.
- the polypeptide-specificity of the present invention obtained by measurement under uniform measurement conditions using a plurality of (at least 2, preferably 3 or more, more preferably 5 or more) normal tissues
- the average or statistical intermediate value of the amount of CTL can be used for comparison as a normal value or reference value.
- CTL is actually induced by measuring the amount of the polypeptide-specific CTL of the present invention in a subject who has been administered the polypeptide or polynucleotide of the present invention. It is.
- the polypeptide of the present invention is used as an indicator that the amount of the polypeptide-specific CTL of the present invention in the subject's tissue is, for example, 2 times or more, preferably 3 times or more higher than those of normal subjects.
- the present invention is also a method for preventing and / or treating cancer in a subject, the group comprising the polypeptide, polynucleotide, CTL, and antigen-presenting cell of the present invention. And a method comprising administering to a subject in need thereof an effective amount of an active ingredient selected from.
- the “subject” in the present invention means any living individual, preferably an animal, more preferably a mammal, more preferably a human individual.
- the subject may be healthy or afflicted with some disease, but when cancer prevention and / or treatment is intended, the subject is typically afflicted with cancer.
- the subject is HLA-A02 positive, HLA-A11 positive and / or HLA-A24 positive.
- the subject has or is at risk of suffering from a BORIS positive cancer belonging to isoform A or C, or subfamily 5 or 6.
- the subject is HLA-A02 positive, HLA-A11 and / or HLA-A24 positive and suffers from a BORIS positive cancer belonging to isoform A or C, or subfamily 5 or 6 Have or are at risk of suffering.
- Examples of the polypeptide, polynucleotide, CTL and antigen-presenting cell of the present invention used in the prevention / treatment method of the present invention include any of those described in the present specification.
- the effective amount in the present invention is, for example, an amount that reduces the symptoms of cancer or delays or stops the progression thereof, and is preferably an amount that suppresses or cures cancer. In addition, an amount that does not cause adverse effects exceeding the benefits of administration is preferred. Such an amount can be appropriately determined by an in vitro test using cultured cells or a model animal such as a mouse or a rat, and such a test method is well known to those skilled in the art.
- the specific dose of the active ingredient depends on various conditions relating to the subject in need thereof, such as severity of symptoms, general health status of the subject, age, weight, subject sex, diet, timing and frequency of administration, It can be determined in consideration of the drug used in combination, the response to treatment, the dosage form, compliance with the treatment, and the like.
- the specific dose is, for example, usually 0.0001 mg to 1000 mg, preferably 0.001 mg to 1000 mg, more preferably 0.1 mg to 10 mg in the case of the polypeptide of the present invention. Is preferably administered once. In the case of the polynucleotide of the present invention, it is usually 0.0001 mg to 100 mg, preferably 0.001 mg to 10 mg, which is preferably administered once every several days to several months.
- any known appropriate administration method such as intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration and the like can be used.
- One aspect of the prevention / treatment method of the present invention further includes a step of selecting an HLA-A02 positive, HLA-A11 positive and / or HLA-A24 positive subject as a subject for prevention / treatment before the administering step. .
- This aspect of the invention may further include the step of determining the HLA type of interest prior to the selecting step.
- the target HLA type can be determined by any known method.
- a subject having a BORIS positive cancer belonging to isoform A or C, or subfamily 5 or 6 is used as the subject of prevention / treatment before the administration step.
- the method further includes a step of selecting.
- This aspect of the invention may further comprise the step of detecting a BORIS positive cancer belonging to isoform A or C or subfamily 5 or 6 in the subject prior to the selecting step.
- the tumor detection method described in (8) above can be used.
- One aspect of the prevention / treatment method of the present invention is that HLA-A02 positive, HLA-A11 positive and / or HLA-A24 positive and isoform A or C, or subfamily 5 is present before the administering step.
- This aspect of the present invention includes the steps of determining the HLA type of the subject and detecting BORIS positive cancer belonging to isoform A or C or subfamily 5 or 6 in the subject prior to the selecting step. Further, it may be included. All patents, applications and other publications mentioned herein are hereby incorporated by reference in their entirety.
- Antibody of the present invention also provides at least a part of BORIS belonging to isoform A or C, or subfamily 5 or 6, preferably SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 76
- the antibody may be a polyclonal antibody or a monoclonal antibody, but is preferably a monoclonal antibody.
- the antibodies of the present invention also include functional fragments of antibodies such as Fab, Fab ′, F (ab ′) 2, Fv, scFv, dsFv, Diabody and sc (Fv) 2.
- functional fragments of antibodies such as Fab, Fab ′, F (ab ′) 2, Fv, scFv, dsFv, Diabody and sc (Fv) 2.
- multimers for example, dimers, trimers, tetramers, polymers
- these functional fragments are also included in the antibody of the present invention.
- the antibody of the present invention can be produced according to a method known in the art.
- an antibody can be obtained by immunizing a rabbit or the like using the whole or a part of the polypeptide represented by SEQ ID NO: 1 or 2 as an immunogen and purifying it from the serum.
- the antibody of the present invention is an antibody that can specifically bind to BORIS belonging to isoform A or C, or subfamily 5 or 6, and BORIS belonging to isoform A or C, or subfamily 5 or 6 It is possible to detect expressing cells, or to detect BORIS itself belonging to isoform A or C, or subfamily 5 or 6. Accordingly, in one embodiment of the present invention, a kit for detecting and / or purifying BORIS protein comprising the antibody of the present invention is provided.
- the kit of the present invention is not particularly limited as long as it contains the antibody of the present invention, and includes any kit known in the art, but is not limited thereto.
- kit known in the art but is not limited thereto.
- ELISA Western blot
- kits used for chromatography, immunostaining, and the like are kits used for chromatography, immunostaining, and the like.
- the kit of the present invention may further include any component suitable for the use of one or two or more kits. Examples of such components include, but are not limited to, Handling of secondary antibodies that may or may not be labeled, coloring reagents, solvents, buffers, positive controls, negative controls, reaction vessels, pretreatment reagents, blocking reagents, slide glasses, cover glasses, etc. Examples include instructions.
- the present invention is based on the knowledge that BORIS proteins, particularly BORIS sf5 and / or sf6 are highly expressed in cells having stem cell nature in cervical cancer and ovarian cancer. Therefore, various techniques based on such knowledge are included in the present invention.
- the present invention relates to an antibody that specifically recognizes BORIS sf5 or sf6.
- Such an antibody can be produced by a method known in the art so as to recognize a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 or 2 or a part thereof as an epitope.
- the present invention relates to a polynucleotide having a sequence complementary to the BORIS gene.
- the BORIS gene particularly a specific subfamily thereof, is particularly strongly expressed in cancer stem cells and is considered to affect stem cell properties. Therefore, it is considered that stem cell nature in cancer stem cells can be suppressed by inhibiting the expression of the BORIS gene.
- the polynucleotide of the present invention can be used as an inhibitory nucleic acid, particularly an siRNA.
- the polynucleotide of the present invention can also be used as a primer or probe for detecting DNA or mRNA of BORIS sf5 and / or sf6 in a sample.
- detecting the levels of BORIS sf5 and / or sf6 mRNA and / or polypeptide in a sample obtained from a subject and BORIS sf5 and / or in normal tissues and / or cells
- the present invention relates to a method for detecting cancer stem cells, comprising comparing the detected level with the reference using the level of sf6 mRNA and / or polypeptide as a reference value.
- a method for detecting the level of mRNA and / or polypeptide a method known in the art may be used. Examples of methods for detecting the level of mRNA include RT-PCR, DNA microarray, Northern blotting and the like.
- the above-mentioned BORIS sf5 and / or sf6 primers and / or probes may be used.
- the method for detecting the level of polypeptide include immunohistochemical staining and Western blotting.
- the above-mentioned BORIS sf5 and / or sf6 specific antibody may be used.
- the present invention detects the levels of BORIS sf5 and / or sf6 mRNA and / or polypeptide in a sample obtained from a subject, and BORIS sf5 and / or in normal tissues and / or cells.
- the present invention relates to a method for detecting a tumor in a subject, which comprises comparing the detected level with the reference using the level of sf6 mRNA and / or polypeptide as a reference value.
- a method for detecting the level of mRNA and / or polypeptide a method known in the art may be used. Examples of methods for detecting the level of mRNA include RT-PCR, DNA microarray, Northern blotting and the like.
- the above-mentioned BORIS sf5 and / or sf6 primers and / or probes may be used.
- the method for detecting the level of polypeptide include immunohistochemical staining and Western blotting.
- the above-mentioned BORIS sf5 and / or sf6 specific antibody may be used.
- the tumor detection method of this embodiment can be performed in place of the method (8). Therefore, you may use for the detection process of the cancer in said (9), for example.
- the present invention relates to a pharmaceutical composition for treating cancer in an organ peculiar to a woman and related to cancer stem cells, comprising a partial peptide of BORIS protein or isoform thereof.
- BORIS is less expressed in cancer testis antigens, especially in tissues other than testis
- the present inventors have made cancers in organs unique to women such as cervical cancer, ovarian cancer, uterine cancer, especially cells having stem cell properties. Has been found to be strongly expressed in cancers including. Therefore, it is expected to exhibit particularly excellent effects such as low side effects and high specificity in the treatment of cancer in organs peculiar to women.
- peptide name-Tet means an HLA tetramer bound to a peptide represented by a peptide name.
- Example 1 Isolation and identification of cancer stem cells
- Isolation of spheroid-forming cells In cervical cancer, sphere formation has been reported as one of the indicators of cancer stem cell markers. Therefore, a spheroid formation assay using a low adhesion culture dish was performed.
- Each cervical cancer cell line (CaSki, TCS, MS751, SKG-IIIb, ME-180 and SiHa) was obtained using a multiwell plate (Ultra Low Attachment 6-well plate, Corning) having an ultra-low adhesion surface.
- Cultured Cells were adherent-cultured and detached with a solution of 0.25% trypsin in 2 mM EDTA, and seeded at 10 3 cells / well in each well.
- a cell group indicated as “sphere” means a cell group isolated from a spheroid formed by non-adherent culture similar to this test.
- the cell group displayed as "bulk” means the cell group obtained by normal adhesion culture.
- cDNA microarray In order to analyze genes highly expressed in the sphere group compared to the bulk group, a cDNA microarray was performed. First, using a commercially available aminoallyl RNA amplification kit ver2 (high yield type) (Sigma Aldrich), total RNA was extracted from each cell according to the instructions attached to the kit. 3 ⁇ g of the obtained total RNA was reverse transcribed using a commercially available oligo dT T7 promoter primer and reverse transcriptase to synthesize cDNA. Next, cRNA was synthesized using T7 RNA polymerase and simultaneously incorporated Cy3 or Cy5 labeled cytidine triphosphate. Through this process, a sample of sphere group cells is labeled with Cy5.
- Example 2 Evaluation of BORIS as a therapeutic target for cancer stem cells
- Human Multiple Tissue cDNA Panels I and II (Clontech) were used as a cDNA library for normal tissues.
- PCR a cDNA mixture containing 0.1-0.5 ⁇ l of cDNA, 0.1 ⁇ l of Taq DNA polymerase (Qiagen) and 12 pmol of primer was first warmed at 94 ° C. for 2 minutes, and then at 94 ° C. for 15 seconds. 30 to 40 cycles of dissociation, annealing at 60 ° C. for 30 seconds, and elongation at 68 ° C. for 30 seconds were performed. SEQ ID NOs: 35 and 36 were used as primers. The results are shown in FIG. It can be seen that BORIS is hardly expressed except in the testis in normal tissues.
- BORIS expression analysis in other cancer cell lines RL95-2 and HEC-1-A as endometrial cancer cell lines, TOV-21G, ES-2, MCAS, Ovcar-3, SMOV- as ovarian cancer cell lines The expression levels of BORIS in the bulk group cells of 2 and SKOV-3 were quantified as relative expression levels, where the expression level in the bulk group cells of TCS was 1, as in (2). The results are shown in FIG. BORIS showed high expression level not only in cervical cancer but also in uterine cancer and ovarian cancer.
- BORIS sf5 expression was enhanced in the sphere group in SBC1 and SBC5, and sf6 expression enhancement was observed in Lc817.
- FIG. 19-2 the expression of BORIS sf5 and sf4a was confirmed, and similarly, the expression of BORIS in lung squamous cell carcinoma and lung adenocarcinoma or the expression enhancement in the sphere group was observed.
- FIG. 19-5 the expression of BORIS was also confirmed in primary cultured cells established from surgically excised lung cancer patients. In particular, in primary 7 cells, enhanced expression was confirmed in several sf in the sphere group. Therefore, it was shown that BORIS can be a very promising antigen for cancer immunotherapy even in lung cancer.
- BORIS sf6 (1) Generation of BORIS isoform overexpression strain Using the Platinum retrovirus expression system including pMXpuro vector and Plat-A cells, BORIS sf1 isoform, B0 isoform, sf4 isoform Retroviral vectors encoding the B3 isoform, the B6 isoform, and the C7 isoform, which are sf6 isoforms, were prepared and introduced into TCS cell lines to produce overexpression strains of the respective BORIS isoforms. When the expression level of the BORIS isoform was confirmed by quantitative PCR, it was confirmed that the expression was about 10,000 times that of the one in which the mock vector was introduced. By the same method, an overexpression strain introduced into the SKG-IIIb cell line was also produced.
- Epitope peptides that are antigen-presented by binding to HLA class I molecules are composed of 8 to 10 amino acids, the second from the N-terminal side, 9 or 10
- the second amino acid is the most important amino acid for binding to HLA class I molecules and is called the anchor motif. It has been reported that this anchor motif varies depending on the type of each HLA class I molecule. For example, an epitope peptide that binds to the HLA-A2 molecule that is most studied worldwide has leucine at the second position from the N-terminus and leucine or valine at the ninth or tenth position. Peptides consisting of ⁇ 10 amino acids are best known.
- the peptide that binds to the HLA-A24 molecule has tyrosine, phenylalanine, methionine, or tryptophan at the second position from the N-terminus, and leucine, isoleucine, tryptophan, or phenylalanine at the ninth or tenth position.
- Peptides of 9 to 10 amino acids having either are best known.
- the peptide having the above HLA-binding anchor motif structure was extracted from the C-terminal sequence (SEQ ID NO: 1) specific to BORIS sf6.
- KLLFIGTIKV KLL peptide: SEQ ID NO: 4
- LLFIGTIKV LLF peptide: SEQ ID NO: 5
- HLA-A2 binding peptide candidates and SFKKLFIGTI (SEQ ID NO: 3) as HLA-A24 binding peptide candidates are extracted by a conventional method. Synthesized.
- HLA-A2 binding assay T2 cells were cultured overnight at 26 ° C. Thereafter, the cells were washed with PBS, and the KLL peptide and LLF peptide synthesized in (3) as HLA-A2-binding peptide candidates, the CMV peptide (SEQ ID NO: 37) which is a cytomegalovirus-derived peptide as a positive control, and influenza virus-derived As a negative control, Influenza (SEQ ID NO: 38) and GK-12 peptide (SEQ ID NO: 39) as an HLA-A24-binding peptide were added, and the cells were co-cultured at 26 ° C. for 3 hours.
- HLA-A2 antibody was added to the isolated cells, and the mixture was allowed to stand at 4 ° C. for 1 hour, and then washed with PBS.
- a fluorescently labeled anti-mouse IgG + IgM antibody was added as a secondary antibody, and the mixture was allowed to stand at 4 ° C. for 30 minutes, and then 1% formalin was added to fix the cells.
- FITC fluorescence intensity of the fixed cells was measured with a flow cytometer (BECTON DIKINSON or Beckman Coulter).
- the analysis was performed in two stages. In the first stage, cells in 8 columns in a 96-well U-bottom cell culture microtest plate were collected as one sample, and the presence or absence of induction of BORIS-specific CTL in this sample was confirmed. The sample in which CTL induction was confirmed at this stage was analyzed in the second stage. In the second stage, cells were individually collected from 8 wells as one sample, and the presence or absence of induction of BORIS-specific CTL was confirmed.
- the analysis results on the flow cytometer are represented by a dot plot development view showing the fluorescence intensity for CD8 on the X-axis and the HLA-tetramer reagent on the Y-axis on a log scale.
- the numbers in the dot plot development diagram indicate the UR for (UR + LR) when the region obtained by dividing the development diagram into four (UL) (upper left), UR (upper right), LL (lower left), and LR (lower right). Percentage, that is, the percentage of cells positive for HLA-tetramer reagent out of cells positive for CD8 is shown.
- FIG. 20 shows the first-stage analysis results of a sample collected from PBMC of specimen No. A2-34 cultured for 13 days with the sequence number 4 of the BORIS sf6-specific CTL epitope candidate peptide.
- a CD8-positive KLL-Tet-positive cell population apparent in specimen No. A2-34 was detected in the URs in lanes 5 and 11. This indicates that the peptide of SEQ ID NO: 4 is a BORIS sf6-specific CTL epitope peptide and BORIS-specific CTL was present in the living body of specimen No. A2-34.
- FIG. 21 shows the results of the second stage of Lane 5 and Lane 11 in which the induction of CTL was confirmed in the first stage analysis.
- KLL peptide SEQ ID NO: 4
- the KLL peptide is a BORIS sf6-specific CTL epitope peptide that exhibits HLA-A * 02: 01 restriction. Since KLL peptide-specific CTL was detected in 2 out of 96 wells, the abundance ratio of KLL peptide-specific CTL in peripheral blood PBMC is calculated by the following equation.
- FIG. 22 shows the first-stage analysis results of a sample collected from PBMC of specimen number A2-29 cultured for 13 days with the sequence number 5 of the BORIS sf6-specific CTL epitope candidate peptide.
- the CD8-positive LLF-Tet-positive cell population apparent in specimen No. A2-29 was found in lane 1, lane 2, lane 4, lane 5, lane 6, lane 7, lane 8, lane 9, lane 10 and lane 11 were detected in UR.
- FIGS. 23-1 and 2 show lane 1, lane 2, lane 4, lane 5, lane 6, lane 7, lane 8, lane 9, lane 10, and lane 11 in which CTL induction was confirmed in the first stage. Represents the result of the second stage.
- Well B in Lane 1 Wells B and D and G and H in Lane 2
- Wells C and F and G in Lane 4 Wells B and F and G in Lane 5
- Wells E and F in Lane 6 Well in Lane 7 L
- LLF peptide (SEQ ID NO: 5) specific CTL was detected in F, wells C and G in lane 8, well C in lane 9, well A in lane 10, and well E in lane 11.
- the AIM-V culture medium refers to a medium in which HEPES (Life Technologies) having a final concentration of 10 mM and 2-mercaptoethanol (Life Technologies) having a final concentration of 50 ⁇ M are added to AIM-V of Life Technologies. Thereafter, only floating cells were collected and CD8 positive cells and negative cells were separated using a magnetic cell separation method using MACS beads (Miltenyi Biotech).
- CD8-negative cells were suspended in AIM-V culture medium, dispensed at about 4 ⁇ 10 5 cells / well in a 48-well plate (Corning), and cultured.
- PHA phytohemagglutinin, Wako
- IL-2 Life Technologies
- IL-2 (Shionogi) having a final concentration of 100 U / mL was added.
- the cells were collected in a culture tube (BD), suspended in 1 mL of AIM-V (Life Technologies), and the peptide of SEQ ID NO: 5 (final concentration 20 ⁇ g / mL) was added. Then, it was left to stand at room temperature for 1 hour, 100 Gy irradiation treatment was performed, and PHA blast cells were prepared.
- CD8 positive cells were cultured in a medium containing AIM-V culture medium supplemented with 10% human AB serum (Lonza Japan), and then suspended in a 48-well plate (Corning) at about 2 ⁇ 10 6. An individual / well was dispensed. On the 8th day from the start of the culture, 10 ng of IL-7 (R & D Systems) was added to each well. Furthermore, CD8 positive cells and PHA blast cells were mixed so that the ratio was 5 to 1, and co-culture was started. Preparation of PHA blast cells is started again on the 9th and 16th days from the start of the culture, and on the 16th and 23rd days when the preparation of the PHA blast cells is completed, CD8 positive cells and PHA blast cells become 5: 1.
- the mixture was mixed again and stimulated with PHA blast cells three times in total.
- 10 U / mL of IL-2 (Shionogi Co., Ltd.) was added, the concentration was increased stepwise, finally the concentration was increased to 50 U / mL, and the culture was continued until the 28th day.
- the cell population cultured for 28 days was stained with PE-labeled HLA-tetramer reagent and CD8-FITC antibody using the same method as in (5) above, and the presence or absence of induction of BORIS sf6-specific CTL in the sample was confirmed. .
- FIG. 24 shows the analysis result of a sample collected from the cell population obtained by culturing the PBMC of specimen number A2-S1 for 28 days with the sequence number 5 of the BORIS sf6-specific CTL epitope candidate peptide.
- the medium for culturing the cells is AIM-V culture medium with a final concentration of 10% human AB serum (Lonza Japan), a final concentration of 1% penicillin / streptomycin (Life Technologies), and a final concentration of 1% GlutaMAX (Life Technologies), IL-2 (Shionogi) with a final concentration of 100 U / mL, and PHA (Wako) with a final concentration of 5 ⁇ g / mL were used.
- 100 Gy irradiated cells were added to 50000 PBMCs collected and collected from 3 healthy donors.
- the cell isolated with the flow cytometer observed the color of the culture medium, and performed medium exchange of the half quantity at any time. Furthermore, when cells increased, the cells were transferred to 48-well plates.
- the cultured CTLs were stained with LLF-Tet and CD8-FITC antibodies using the same method as in (5) above, and the results of confirming CTL amplification are shown in FIG. As a result, a clear CD8 positive LLF-Tet positive cell population was detected. This indicates that the BORIS-derived LLF peptide-specific CTL was successfully cloned and amplified.
- FIG. 27 shows the result of processing the cultured CTL in the same procedure as in (7) above and analyzing the function of the CTL.
- the cultured CTL is a CTL specific to the LLF peptide (SEQ ID NO: 5) that produces IFN ⁇ by restimulation of the LLF peptide.
- LLF peptide-specific CTL (9) Functional analysis of LLF peptide-specific CTL It was analyzed by LDH killing assay (TaKaRa Bio) whether the LLF peptide-specific CTL that had been cultured in (8) attacked the cells presenting the LLF peptide.
- a target cell (Target) to be attacked by LLF peptide-specific CTL was prepared. Three types of cells were prepared: T2 cells pulsed with the LLF peptide of SEQ ID NO: 5 and, as a negative control thereof, HIV-derived peptide (SLY peptide) pulsed to T2 cells, and T2 cells alone. Target cells were seeded at 1 ⁇ 10 4 cells / well in a 96-well V-bottom plate (Corning).
- LLF-specific CTL cell suspensions having a concentration of 9 ⁇ 10 5 cells / mL, 3 ⁇ 10 5 cells / mL, 1 ⁇ 10 5 cells / mL were prepared, and 100 ⁇ L of each well was seeded. Mixed with target cells seeded in well plate. Thereafter, the 96-well plate was centrifuged at 1800 rpm for 10 minutes, and then allowed to stand for 4 to 12 hours in a 37 ° C. CO 2 incubator. The 96-well plate was centrifuged to precipitate the cells, and then 100 ⁇ L of the supernatant was transferred to a flat-bottom 96-well plate.
- the result is shown in FIG.
- the X-axis shows the ratio of Effector and Target cells in terms of E / T ratio
- the Y-axis shows cytotoxic activity (%).
- the cytotoxic activity can be calculated according to the following formula. [Measured value of sample (absorbance at 490 nm: A490) ⁇ low control (A490)] / [high control (A490) ⁇ low control (A490)] ⁇ 100.
- the high control (A490) shows the measured value of the target cell suspension with 2% Triton X-100
- the low control (A490) shows the target cell suspension.
- the cytotoxic activity (%) value was shown as an average value of 3 samples.
- the LLF peptide-specific CTL is compared with the case where T2 cells pulsed with a negative control HIV-derived peptide (SLY peptide) are used as target cells or T2 cells to which no peptide is added are used as target cells.
- SLY peptide negative control HIV-derived peptide
- T2 cells pulsed with a peptide were used as target cells, cytotoxic activity was shown at a high rate. That is, it was revealed that cancer cells on which the LLF peptide (SEQ ID NO: 5) was presented were specifically recognized and exhibited cytotoxic activity.
- Example 4 Examination of BORIS sf5 (1) Extraction of BORIS-specific HLA-binding epitope candidates BORIS-specific HLA-binding epitope candidates BORIS-specific HLA-binding epitope candidates were extracted in the same manner as in Example 3 (3) above. As the BORIS to be analyzed, the BORIS B1 isoform (subfamily 5) which has the longest amino acid sequence and is also a candidate for BORIS expressed specifically in cancer stem cells is used. About 60% of Japanese people Were extracted and synthesized as epitope candidates having binding properties to HLA-A * 24: 02 retained by the above. The synthesized peptides are shown below.
- Table 5 shows the characteristics of the synthesized BORIS HLA-A * 24: 02 binding peptide.
- the abbreviation with the peptide name of 3 or 4 amino acid sequences from the N-terminal side of the synthesized peptide is shown. From left, peptide name, amino acid sequence, position on BORIS isoform B1 amino acid sequence, number of amino acids, BIMAS used for analysis (BioInformatics & Molecular Analysis Section, http://thr.cit.nih.gov/index.shtml)
- the score calculated by HLA Peptide Binding Predictions http://thr.cit.nih.gov/molbio/hla_bind/) is shown. This score is a numerical value that predicts the affinity between HLA-A * 24: 02 and the peptide. The higher the score, the more likely the HLA and peptide form a stable complex.
- HLA-A * 24 02 (60 mg / L), ⁇ 2-microglobulin (20 mg / L), and BORIS-specific CTL epitope candidate peptide (30 ⁇ M), which were expressed and purified using an E. coli expression system, were folded.
- HLA molecules and ⁇ 2-microglobulin are solubilized with 8M urea when expressed and purified using an E. coli expression system, but HLA molecules that are sparingly soluble are HLA- Those that do not lead to monomer formation are detected as aggregates at 7-8 minutes, then the HLA-monomer peak is detected around 10 minutes and ⁇ 2-microglobulin is detected around 14 minutes. After 15 minutes, the components and peptides of the folding solution are detected. Therefore, the result is a bar graph showing the value obtained by converting the peak area of the peak around 10 minutes indicating the formation of HLA-monomer to the estimated HLA-monomer formation amount (mg).
- HLA-A * 24: 02 HLA-A * 24: 02, ⁇ 2-microglobulin, and a BORIS-specific CTL epitope candidate peptide were added to the folding solution and mixed to form an HLA-monomer.
- the expressed protein was designed so that a biotin-binding site was added to the C-terminal side of the recombinant HLA-A * 24: 02 molecule, and biotin was added to the site after HLA-monomer formation.
- Dye-labeled streptavidin and the biotinylated HLA-monomer were mixed at a molar ratio of 1: 4 to obtain an HLA-tetramer reagent.
- Peripheral blood was collected from 7 healthy adults known to have HLA-A * 24: 02 and centrifuged at 3,000 rpm for 5-10 minutes. The plasma portion of the supernatant was collected. PBMCs were separated from portions other than plasma by density gradient centrifugation.
- FIG. 12-1 shows the first-stage analysis results of a sample collected from PBMC of specimen No. A24-38 cultured for 13 days with SEQ ID No. 10 of the BORIS-specific CTL epitope candidate peptide.
- the figure is represented by a dot plot development diagram showing the fluorescence intensity for CD8 on the X axis and the HLA-tetramer reagent on the Y axis in log scale.
- the numbers in the dot plot development diagram indicate the area obtained by dividing the development diagram into four parts.
- the percentage of UR for (UR + LR), that is, HLA-tetramer positive cells among CD8 positive cells Indicates the percentage.
- the CD8-positive RMM-Tet-positive cell population apparent from specimen No. A24-38 was found in lane 2, lane 4, lane 8, and lane 9 UR. Detected. This indicates that the peptide of SEQ ID NO: 10 is a BORIS-specific CTL epitope peptide, and BORIS-specific CTL was present in the living body of specimen No. A24-38.
- FIG. 12-2 shows the result of the second stage, which is a result of further analysis for Lane 2, Lane 4, Lane 8, and Lane 9 in which CTL induction was confirmed in the first stage.
- RMM peptide SEQ ID NO: 10
- specific CTL was detected in H in lane 2, G and H in lane 4, F in lane 8, and A well in lane 9. This proves that the RMM peptide is a BORIS-specific CTL epitope peptide that exhibits HLA-A * 24: 02 restriction. Since RMM peptide-specific CTL was detected in 5 out of 96 wells, the abundance ratio of RMM peptide-specific CTL in peripheral blood PBMC is calculated by the following equation.
- EBV-infected LCL EBV-infected B cell line
- the induced CTL was stained in the same manner as in Example 3 (5), and the presence or absence of induction of BORIS sf5-specific CTL in the sample was confirmed.
- FIG. 29 shows that the PBMCs of specimen number A24-S4 holding HLA-A * 24: 02 or specimen numbers A2-S5 holding HLA-A * 02: 01 are RMM peptides (SEQ ID NO: 10) It is an analysis result of the cell population which co-cultured with the presentation cell for 28 days. The presence or absence of RMM peptide-specific CTL induction in specimen numbers A24-S4 and A2-S5 was analyzed using HLA tetramer reagents produced using RMM peptides corresponding to the HLA type possessed by each specimen. did. As a result, a clear CD8-positive RMM-Tet-positive cell population was detected for both specimen numbers A24-S4 and A2-S5.
- SEQ ID NO: 10 is a BORIS sf5-specific CTL epitope peptide, and BOIRS-specific CTL was present in the living bodies of specimen numbers A24-S4 and A2-S5. It was also found that the peptide of SEQ ID NO: 10 has binding properties to both HLA-A * 24: 02 and HLA-A * 02: 01 HLA types.
- BOIRS-specific CTL The functional analysis of BOIRS-specific CTL was carried out using the ELISPOT Set (BD) kit in the same procedure as in Example 3 (7), and IFN ⁇ secreted by the RMM peptide-specific CTL was spotted and measured.
- BD ELISPOT Set
- FIG. 30 shows the result of representing the number of spots in a bar graph.
- a negative control HIV-derived peptide (RYL peptide for sample A24-S4, SLY peptide for sample A2-S5) is added, or when stimulated with RMM peptide compared to no peptide added (PBS) The number of spots was clearly detected.
- the RMM peptide is the 670th to 678th amino acids of the BORIS B1 isoform.
- BORIS B1 is an isoform consisting of 700 amino acids belonging to BORIS subfamily 5
- BORIS sf5 is a subfamily-specific sequence at 132 amino acids on the C-terminal side, particularly 38 amino acids on the C-terminal side (SEQ ID NO: 2).
- the RMM peptide is a sequence specific to BORIS sf5, and cancer stem cells derived from ovarian cancer that have been found to specifically express BORIS sf5 according to the present invention are also targeted. It is an epitope peptide capable of inducing CTL.
- BORIS C1 isoform (1) Extraction of BORIS-specific HLA-binding epitope candidates As the BORIS to be analyzed, BORIS C1 isoform (subfamily 1, SEQ ID NO: 76) was used, and HLA-A * was used as the HLA type. A BORIS-specific HLA-binding epitope candidate was extracted in the same manner as in Example 3 (3) except that 02:01 was used. The synthesized peptides are shown below.
- Table 7 shows the characteristics of the synthesized BORIS HLA-A * 02: 01 binding peptide.
- the abbreviations with 3 to 4 amino acid sequences from the N-terminal side of the synthesized peptide are shown as peptide names. From left, peptide name, amino acid sequence, position on BORIS C1 isoform amino acid sequence, number of amino acids, SYFPEITHI used for analysis (http://www.syfpeithi.de/0-Home.htm) EPITOPE PREDICTION (http: //www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm).
- This score is a numerical value that predicts the affinity of HLA and peptide with the structural motif of HLA-A * 02: 01 molecule and peptide. The higher the score, the more likely the HLA and peptide form a stable complex. Means that.
- FIG. The result shows a value converted to an estimated HLA-monomer formation amount (mg) as in Example 4 (2).
- mg estimated HLA-monomer formation amount
- Example 4 (2) As a result, sufficient HLA-monomer formation was observed in 10 types of BORIS-specific CTL epitope candidate peptides of SEQ ID NO: 47 to SEQ ID NO: 57, except for SEQ ID NO: 55, as compared with the negative control. That is, it was shown that the BORIS-specific CTL epitope candidate peptides listed in Table 7 other than the MAA peptide bind to HLA-A * 02: 01.
- the cell population in which CTL was induced was checked for the presence or absence of CTL in the same manner as in Example 3 (5).
- CTL staining was performed using an HLA-tetramer reagent corresponding to the BORIS-specific CTL epitope candidate peptide used in the induction. Below, the typical result in which the induction
- FIG. 34 shows specimen number A2-29
- FIG. 36 shows specimen number A2-27
- FIG. 38 shows specimens obtained by culturing PBMCs collected from specimen number A2-34 with the BORIS-specific CTL epitope candidate peptide SEQ ID NO: 47 for 13 days. Represents the results of the first stage analysis of the sample.
- VLE-Tet a clear CD8-positive VLE-Tet-positive cell population was found in lane 10 in specimen number A2-29, and in lane 3 in specimen number A2-27. , Detected in the UR of Lane 4 with specimen number A2-34.
- 35, 37, and 39 show the results of the second stage of the lane in which the induction of CTL was confirmed in the first stage.
- VLE peptide (SEQ ID NO: 47) specific CTL was detected in well H of lane 10, in well E of lane 3 in FIG. 37, and in well C of lane 4 in FIG. This proves that the VLE peptide is a BORIS-specific CTL epitope peptide that exhibits HLA-A * 02: 01 restriction.
- VLE peptide-specific CTL was detected in 1 out of 96 wells, so the abundance ratio of VLE peptide-specific CTL in peripheral blood PBMC is calculated by the following equation.
- FIG. 40 shows the first-stage analysis results of a sample collected from PBMC collected from specimen No. A2-29 and cultured for 13 days with SEQ ID No. 48 of the BORIS-specific CTL epitope candidate peptide.
- SEQ ID No. 48 of the BORIS-specific CTL epitope candidate peptide.
- FIG. 41 shows the result of the second stage of the lane in which CTL induction was confirmed in the first stage.
- CTL specific for KLA peptide SEQ ID NO: 48
- SEQ ID NO: 48 CTL specific for KLA peptide
- the KLA peptide is a BORIS-specific CTL epitope peptide that exhibits HLA-A * 02: 01 restriction. Since KLA peptide-specific CTL was detected in 3 out of 96 wells, the abundance ratio of KLA peptide-specific CTL in peripheral blood PBMC is calculated by the following equation.
- FIG. 42 shows the first-stage analysis results of a sample collected from PBMC collected from specimen number A2-29 and cultured for 13 days with SEQ ID NO: 57 of the BORIS-specific CTL epitope candidate peptide.
- SEQ ID NO: 57 When the induction of specific CTL of SEQ ID NO: 57 was confirmed with VLT-Tet, a clear CD8-positive VLT-Tet-positive cell population was detected in UR of lane 7 and lane 9 with sample number A2-29. This indicates that the peptide of SEQ ID NO: 57 is a BORIS-specific CTL epitope peptide, and BOIRS-specific CTL was present in the living body of specimen No. A2-29.
- FIG. 43 shows the result of the second stage of the lane in which CTL induction was confirmed in the first stage.
- VLT peptide SEQ ID NO: 57
- the VLT peptide is a BORIS-specific CTL epitope peptide that exhibits HLA-A * 02: 01 restriction. Since VLT peptide-specific CTL was detected in 2 out of 96 wells, the abundance ratio of VLT peptide-specific CTL in peripheral blood PBMC is calculated by the following equation.
- an anti-CD107a-FITC-labeled antibody and monensin were added to both the peptide-added well and the untreated well, and cultured for 4 hours in a 37 ° C. CO 2 incubator. After culturing, the cells were washed, PE-labeled HLA-tetramer reagent corresponding to each peptide and PC5 (phycoerythrin-Cy5) -labeled anti-CD8 antibody (Beckman Coulter) were added, and left at room temperature for 15-30 minutes. . After washing with an excessive amount of washing solution, CD107a, which is a CTL degranulation marker, was detected using a flow cytometer, and the positive cell rate was calculated. CTL is known to express on a cell membrane CD107a present in the inner lining of cells when releasing cytotoxic factors such as perforin and granzyme, and by detecting CD107a molecule, Injury factor release can be examined indirectly.
- Results are shown in FIG. 44 and FIG.
- CD107a-positive HLA-tetramer reagent-positive cells appeared in the UR, and hardly appeared when the KLA peptide was not added. This shows that CTL that specifically reacts with KLA-Tet is induced when stimulated with KLA peptide.
- FIG. 45 only when stimulated with the VLT peptide, CD107a-positive HLA-tetramer reagent-positive cells appeared in the UR, and hardly appeared when the VLT peptide was not added. This shows that CTL that specifically react with VLT-Tet is induced when stimulated with VLT peptide.
- Table 8 shows a summary of the results of studies on the induction of HLA-A * 02: 01-restricted BORIS-specific CTL.
- Table 9-1 shows the characteristics of the synthesized BORIS-specific HLA-A * 11: 01 binding epitope candidates.
- the peptide that binds to HLA-A11 has either Ile, Met, Ser, Thr, or Val located at the second position from the N-terminal, and either Lys or Arg located at the ninth or tenth position. It is known that there are many cases.
- the peptide consists of 9 to 10 amino acids (see Rapin N et al., Curr Protoc Immunol. 2010; Chapter 18: Unit 18.17). The abbreviations with 3 to 4 amino acid sequences from the N-terminal side of the synthesized peptide are shown as peptide names.
- This score is a numerical value that predicts the affinity between HLA-A * 11: 01 and the peptide. The higher the score, the more likely the HLA and peptide are to form a stable complex.
- the NetMHC 3.4 scores shown in Tables 9-1 and 9-2 are shown as representative examples obtained with 11 types of analysis software used in the analysis.
- FIG. 46 shows the analysis results after 1, 3, and 7 days of the folding test performed on 15 types of peptides.
- CMV pp65 protein-derived HLA-A * 11: 01 restricted peptide ATV peptide, SEQ ID NO: 73
- AYA peptide 02 restricted peptide
- the BORIS-specific CTL epitope candidate peptides (SEQ ID NO: 60 to SEQ ID NO: 72) were found to have sufficient HLA-monomer formation as compared to the negative control. That is, the BORIS-specific CTL epitope candidate peptides listed in Table 9-1 were shown to bind to HLA-A * 11: 01.
- HLA-tetramer mixed reagent 1 (SVL-Tet, NTH-Tet, KQL-Tet and GLI-Tet) or HLA-tetramer mixed reagent 2 (SLA-) corresponding to the four types of mixed peptides used for induction of this sample
- SLA- HLA-tetramer mixed reagent 1
- SLA- HLA-tetramer mixed reagent 2
- a second stage analysis was performed on the samples in which induction of CTL was confirmed at this stage.
- cells were individually collected from 8 wells as one sample, and this sample was stained with HLA-tetramer mixed reagent 1, 2, or 3 to confirm the presence or absence of induction of BORIS-specific CTL.
- the cells in the wells in which induction of CTL was confirmed in the second stage reacted with which HLA-tetramer reagent of the HLA-tetramer mixed reagent, or the CTL was detected separately using the HLA-tetramer reagent. Carried out. Using this method, it was confirmed in which well of a 96-well U-bottom cell culture microtest plate that CTL having specificity for which peptide was induced.
- FIG. 47 shows the analysis result of the first stage.
- the analysis result of the first stage of the sample collected from the PBMCs of specimen number * 11-13 cultured with 4 kinds of mixed peptides 1 for 14 days is shown.
- HLA-tetramer mixed reagent 1 When stained with HLA-tetramer mixed reagent 1 in the same manner as in Example 3 (5), a clear CD8-positive HLA-tetramer mixed reagent 1-positive cell population was detected in the UR of lane 1.
- This result shows that at least one CTL epitope is present in the BORIS-specific CTL epitope candidates used in the study, and that the BORIS-specific CTL is present in the living body of specimen number A * 11-13. It indicates that it existed.
- FIG. 48 shows the second-stage analysis result of Lane 1 in which CTL induction was confirmed in the first-stage analysis.
- well B (1-B) in lane 1 the induction of CTL specific for the HLA-A * 11: 01 binding BORIS-specific CTL epitope was confirmed.
- FIG. 49 shows the results of the third stage analysis of well B in lane 1 where CTL induction was confirmed in the second stage analysis. As a result, CTL was confirmed only when stained with KQL-Tet. This demonstrates that the KQL peptide (SEQ ID NO: 66) is an HLA-A * 11: 01 restricted BORIS-specific CTL epitope peptide.
- FIG. 50 shows the analysis result of the first stage.
- the analysis results of the first stage of the samples collected from the PBMCs of specimen number * 11-13 cultured with 4 kinds of mixed peptides 2 for 14 days are shown.
- HLA-tetramer mixed reagent 2 in the same manner as in Example 3 (5), a clear CD8-positive HLA-tetramer mixed reagent 2-positive cell population was detected in the UR of lane 12.
- This result shows that at least one CTL epitope is present in the BORIS-specific CTL epitope candidates used in the study, and that the BORIS-specific CTL is present in the living body of specimen number A * 11-13. It indicates that it existed.
- FIG. 51 shows a second-stage analysis result of lane 12 in which CTL induction was confirmed in the first-stage analysis.
- well E (12-E) in lane 12 the induction of CTL specific for the HLA-A * 11: 01 binding BORIS-specific CTL epitope was confirmed.
- FIG. 52 shows the results of the third stage analysis of well E in lane 12 where CTL induction was confirmed in the second stage analysis. CTLs were confirmed only when stained with TVY-Tet. This demonstrates that the TVY peptide (SEQ ID NO: 67) is an HLA-A * 11: 01 restricted BORIS specific CTL epitope peptide.
- FIG. 53 shows the analysis result of the first stage.
- the analysis results of the first stage of a sample collected from the PBMCs of specimen number * 11-16 cultured for four days with four types of mixed peptides 3 are shown.
- HLA-tetramer mixed reagent 3 When stained with HLA-tetramer mixed reagent 3 in the same manner as in Example 3 (5), a clear CD8-positive HLA-tetramer mixed reagent 3-positive cell population was detected in URs in lanes 7 and 11.
- This result shows that at least one CTL epitope is present in the BORIS-specific CTL epitope candidates used for the study, and that a BORIS-specific CTL exists in the living body of specimen number A * 11-16. It indicates that it existed.
- FIG. 54 shows the second-stage analysis results of Lane 7 and Lane 11 in which CTL induction was confirmed in the first-stage analysis.
- the well E (7-E) in lane 7 and the well H (11-H) in lane 11 induction of CTL specific for the HLA-A * 11: 01 restricted BORIS-specific CTL epitope was confirmed.
- FIG. 55 shows the third-stage analysis results of well E in lane 7 and well H in lane 11 where CTL induction was confirmed in the second-stage analysis.
- Well E in lane 7 confirmed CTL only when stained with GTM-Tet
- well H in lane 11 confirmed CTL only when stained with KLLF-Tet.
- GTM peptide SEQ ID NO: 65
- KLLF peptide SEQ ID NO: 72
- Example 6 Preparation of specific antibodies for BORIS sf5 and sf6
- a peptide sequence composed of 8 to 20 amino acids from SEQ ID NO: 1 and SEQ ID NO: 2 was synthesized.
- a cysteine residue was added to the C-terminal or N-terminal, and KHL (Keyhole limpet hemocyanin) was bound according to a conventional method to be used as an immunogen.
- Rabbits and guinea pigs were immunized every other week or 4-6 times weekly. After completion of immunization, blood was collected from each individual and purified with an affinity column made of a peptide used as an immunogen to obtain a specific antibody.
- the specificity was verified using a cell extract of cultured cells 293T in which BORIS sf5 and BORIS sf6 were each transiently expressed and a cell extract of untreated 293T cells.
- a Myc Tag sequence was added to the transiently expressed BORIS sf5 and BORIS sf6 genes, and a Myc Tag antibody specific for this was used as a positive control.
- the obtained BORIS sf5 and BORIS sf6 specific antibodies were both detected by the positive control when the extract of each BORIS expression 293T cell was used. A band was detected at the position showing the same molecular size as in the above, whereas no band was detected in the untreated 293T cell extract. From this, it was considered that antibodies that specifically bound to BORIS sf5 and BORIS sf6 could be obtained.
- the cancer affected part tissue section excised from the lung cancer patient was stained with a BORIS sf5-specific antibody, it was found that it may be determined as negative or positive (see FIG. 57).
- Example 7 Preparation of siRNA against BORIS sf6 (1) Design of siRNA siRNA against BORIS designed to have the sequence shown in the table below was applied to MS751 and CaSki respectively according to the protocol described in the manufacturer's instructions using Lipofectamine RNAiMAX. Transfected. Cells were analyzed 48 hours after transfection. Trilencer-27 Universal Scrambled Negative Control siRNA (SR30004, Origene) was used as a negative control.
- FIGS. FIG. 14-1 (a) shows that the expression level of BORIS (B0) is remarkably suppressed by three types of siRNA (quantitative RT-PCR).
- siRNA1 and siRNA2 some cell growth inhibition was observed with siRNA1 and siRNA2.
- the greater the number of BORIS subfamilies that are being suppressed the higher the growth inhibitory effect.
- no suppression of stem cell genes occurred (FIG. 15).
- the sphere-forming ability of CasKi and MS751 was remarkably suppressed by siRNA2 (not necessarily consistent with the results of cell growth suppression).
- siRNA 1-3 knockdown was not related to radiation resistance (FIG. 17).
- FIG. 18 shows that the survival rate is significantly lowered when the BORIS expression is high. Therefore, BORIS is recognized as a significant poor prognostic factor.
- the present invention can provide an effective therapeutic agent for various cancers.
- CTLs induced by the epitope peptides of the present invention can induce CTLs that can specifically attack various cancer cells, particularly cancer stem cells that are the cause of malignant tumors, It is very useful as an effective anticancer agent with few side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
Abstract
Description
[1]アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS遺伝子を発現する細胞を特異的に認識するCTLを誘導する方法であって、以下の(a)または(b):
(a)前記BORISタンパク質の部分ペプチドであって、8~20アミノ酸長であり、HLA結合能を有するポリペプチド、
(b)上記(a)記載のポリペプチドの少なくとも一つをコードするポリヌクレオチド、
のいずれかと、末梢血リンパ球とを接触させることを含む、前記方法。
[2]in vitroで行われる、[1]の方法。
[3][1]または[2]の方法に用いるポリペプチドであって、配列番号1または配列番号2で表されるポリペプチドの部分ペプチドであり、8~20アミノ酸長であり、HLA結合能を有する、前記ポリペプチド。
[4]8~11アミノ酸長である、[3]のポリペプチド。
[5]配列番号1で表されるポリペプチドの部分ペプチドである、[3]または[4]のポリペプチド。
[6]配列番号3、配列番号4、配列番号5または配列番号72で表される、[5]のポリペプチド。
[7]配列番号2で表されるポリペプチドの部分ペプチドである、[3]または[4]のポリペプチド。
[8]配列番号10で表される、[5]のポリペプチド。
[9][1]または[2]の方法に用いるポリペプチドであって、HLA-A11抗原結合能を有する、前記ポリペプチド。
[10]配列番号65、配列番号66、配列番号67または配列番号72で表される、[9]のポリペプチド。
[11][1]または[2]の方法に用いるポリペプチドであって、HLA-A2抗原結合能を有し、配列番号4、配列番号5、配列番号10、配列番号47または配列番号57で表される、前記ポリペプチド。
[12][1]または[2]の方法に用いるポリペプチドであって、HLA-A24抗原結合能を有する、前記ポリペプチド。
[13]配列番号3または10で表される、[12]のポリペプチド。
[14][3]~[13]のポリペプチドにおいて1または複数のアミノ酸が付加、欠失、置換された、前記ポリペプチド。
[15][1]または[2]の方法に用いるポリヌクレオチドであって、[3]~[14]のポリペプチドをコードする、前記ポリヌクレオチド。
[16][3]~[14]のポリペプチドの少なくとも1つを有効成分として含む、細胞傷害性T細胞(CTL)誘導剤。
[17][16]のCTL誘導剤を有効成分として含む医薬組成物。
[18][16]のCTL誘導剤を有効成分として含む、がん幹細胞処置用組成物。
[19][16]のCTL誘導剤を有効成分として含む、がんの予防および/または治療用組成物。
[20][1]または[2]の方法で誘導した細胞傷害性T細胞(CTL)を有効成分として含む、がんの予防および/または治療用組成物。
[21]がんが、女性特有の臓器におけるがんまたは肺がんである、[19]または[20]のがんの予防および/または治療用組成物。
[22][15]のポリヌクレオチドを含有する発現ベクター。
[23][15]のポリヌクレオチド、または[22]の発現ベクターのいずれかを有効成分として含有する、がんの治療または予防のための医薬組成物。
[24][3]~[14]のポリペプチドとHLAとを含有するHLA-テトラマー。
[25]以下の(a)または(b):
(a)[3]~[14]のポリペプチド
(b)上記(a)記載のポリペプチドの少なくとも1つをコードするポリヌクレオチド、
と、抗原提示能を有する細胞とを、in vitroで接触させることを含む、抗原提示細胞の製造方法。
[26]配列番号1または配列番号2で表されるポリペプチドの少なくとも一部と特異的に結合する抗体。
[27][26]の抗体を含む、BORISタンパク質検出用キット。
(1)本発明のポリペプチド
本発明において「エピトープペプチド」とは、MHC(ヒトにおいてはHLA)と結合して、細胞表面に抗原提示されるポリペプチドを意味する。エピトープペプチドには、MHCクラスIと結合して抗原提示され、CD8陽性T細胞に認識されるエピトープペプチドであるCTLエピトープペプチド、およびMHCクラスIIと結合して抗原提示され、CD4陽性T細胞に認識されるエピトープペプチドであるヘルパーエピトープペプチドが含まれる。
エピトープペプチドのうち、腫瘍細胞において特異的にあるいは過剰に発現しているタンパク質由来のポリペプチドを、特に腫瘍抗原ペプチドという。抗原提示とは、細胞内に存在するポリペプチドがMHCと結合し、このMHC/抗原ペプチド複合体が細胞表面に局在化する現象をいう。上述のとおり、細胞表面に提示された抗原はT細胞などにより認識された後、細胞性免疫や液性免疫を活性化することが知られており、MHCクラスIに提示された抗原は、細胞性免疫を活性化するとともに、ナイーブT細胞のT細胞受容体に認識され、ナイーブT細胞を、細胞傷害活性を有するCTLへと誘導するため、免疫療法に用いられる腫瘍抗原ペプチドとしては、MHCクラスIと結合し、抗原提示されるポリペプチドが好ましい。
本発明において、「腫瘍(tumor)」は、良性腫瘍および悪性腫瘍(がん、悪性新生物)を含む。がん(cancer)は、造血器の腫瘍、上皮性の悪性腫瘍(癌、carcinoma)と非上皮性の悪性腫瘍(肉腫、sarcoma)とを含む。
上述のとおり、本発明のポリペプチドはMHCに結合する前にプロセシングなどの処理を経てもよいため、エピトープペプチドのアミノ酸配列を含む配列であれば、アミノ酸長は特に限定されない。しかしながら、本発明のポリペプチドそのものがエピトープペプチドであることが好ましく、したがってアミノ酸長は約8~約20アミノ酸程度が好ましく、約8~約11アミノ酸程度がより好ましく、約8~約10アミノ酸程度がさらに好ましい。
別の好ましい一態様において、本発明のポリペプチドは、配列番号2で表されるポリペプチドの部分ペプチドであって、8~11アミノ酸長であり、HLA結合能を有するポリペプチドである。
本態様のポリペプチドのうち、HLA-A24抗原に対する結合能を有するポリペプチドとしては、これに限定するものではないが、配列番号3または配列番号10で表されるポリペプチドなどが挙げられる。
HLA抗原、とくにHLAクラスI抗原に結合性を有するペプチドは、特定の位置に特定のアミノ酸を有していることが知られており、これはアンカーモチーフと呼ばれ、あるアンカーモチーフを別のアンカーモチーフに置き換えてもHLA結合能を失わないと考えられる。したがって本発明のペプチドにおける付加、欠失、置換としては、アンカーモチーフを別のアンカーモチーフに置き換える付加、欠失、置換が好ましい。例えばHLA-A11抗原結合性を有するポリペプチドにおいては、N末端より2番目の位置にIle、Met、Ser、ThrまたはValのいずれかが配置され、9番目あるいは10番目の位置にLysまたはArgのいずれかが配置されることが多いことが知られており、上記好ましい付加、欠失、置換としては例えばN末端より2番目の位置に存在するIleをMet、Ser、ThrまたはValに置換するものが挙げられる。
(a)HLA-A11抗原結合性ペプチドにおいて、N末端より2番目の位置のペプチドをIle、Met、Ser、ThrまたはValとするもの;
(b)HLA-A11抗原結合性ペプチドにおいて、N末端より9番目あるいは10番目のペプチドをLysまたはArgとするもの;
(c)HLA-A24抗原結合性ペプチドにおいて、N末端より2番目の位置のペプチドをTrp、Phe、MetまたはTyrとするもの;
(d)HLA-A24抗原結合性ペプチドにおいて、N末端より9番目あるいは10番目のペプチドをPhe、Leu、IleまたはTrpとするもの;
(e)HLA-A2抗原結合性ペプチドにおいて、N末端より2番目の位置のペプチドをIle、Val、AlaまたはThrとするもの;および/または
(f)HLA-A2抗原結合性ペプチドにおいて、N末端より9番目あるいは10番目のペプチドをVal、Leu、Ile、AlaまたはMetとするもの
などが挙げられる。
本発明のポリペプチドは、後述するCTL誘導方法や、ヒトモデル動物を用いたアッセイ(WO02/47474号公報、Int J. Cancer:100,565-570 (2002))等に供することにより、in vivoでの活性を確認することができる。
本発明のポリヌクレオチドは、前記本発明のポリペプチドを少なくとも1つコードするポリヌクレオチドを含む。本発明のポリヌクレオチドは、cDNAやmRNA、cRNA、または合成DNAのいずれであっても良い。また1本鎖、2本鎖のいずれの形態であっても良い。具体的には、例えば配列番号3、配列番号4、配列番号5、配列番号10、配列番号47、配列番号48、配列番号57、配列番号65、配列番号66、配列番号67または配列番号72に記載のアミノ酸配列をコードするヌクレオチド配列からなるポリヌクレオチドを、それぞれ発現可能なようにコードするヌクレオチド配列からなるポリヌクレオチドなどが挙げられる。本発明のポリヌクレオチドは、一態様において、遺伝子組換え技術を用いて本発明のポリペプチドを宿主内で産生させるために用いられる。この場合、宿主間でアミノ酸コドンの使用頻度が異なる為、産生させる宿主の使用頻度に適合するようアミノ酸のコドンを変更してもよい。
本発明のポリヌクレオチドは、本明細書に記載のとおり、がんの予防および/または治療などに有用であり、医薬組成物の有効成分とすることができる。また、本発明のポリヌクレオチドは、がんの予防および/または治療のためのものであってもよい。さらに、本発明は、がんの予防および/または治療のための医薬の製造への本発明のポリヌクレオチドの使用にも関する。
宿主細胞への発現ベクターの導入方法としては、前記宿主細胞に適合した通常の導入方法を用いれば良い。具体的にはリン酸カルシウム法、DEAE-デキストラン法、エレクトロポレーション法、遺伝子導入用リピッド(Lipofectamine、Lipofectin; Gibco-BRL社)を用いる方法(リポフェクション法)などが挙げられる。導入後、選択マーカーを含む通常の培地にて培養することにより、前記発現ベクターが宿主細胞中に導入された形質転換細胞を選択することができる。
本発明のポリペプチドをコードするポリヌクレオチドは、DNAの形態であってもRNAの形態であっても良い。これら本発明のポリヌクレオチドは、本発明のポリペプチドのアミノ酸配列情報およびそれによりコードされるDNAの配列情報に基づき、当該技術分野において知られた通常の方法を用いて容易に製造することができる。具体的には、通常のDNA合成やPCRによる増幅などによって、製造することができる。
本発明のポリペプチドをコードするポリヌクレオチドは、前記エピトープペプチドをコードするポリヌクレオチドを包含する。
本発明のポリペプチドは上述のとおり、がん細胞に対するCTLを誘導する方法において用いることができるものであるため、腫瘍抗原ペプチドとしてCTL誘導剤となり得る。
すなわち、ヒト血液試料から末梢血リンパ球を単離し、in vitroで本発明のポリペプチドを添加して刺激することにより、該ペプチドをパルスしたHLA抗原陽性細胞を特異的に認識するCTLを誘導することができる(J.Immunol.,154,p2257,1995)。ここでCTLの誘導の有無は、例えば、抗原ペプチド提示細胞に反応してCTLが産生する種々のサイトカイン(例えばIFNγ)の量を、例えばELISA法などによって測定することにより、確認することができる。また51Crで標識した抗原ペプチド提示細胞に対するCTLの傷害性を測定する方法(51Crリリースアッセイ、Int.J.Cancer,58:p317,1994)によっても確認することができる。
また、Int. J. Cancer, 39, 390-396, 1987, N. Eng. J. Med, 333, 1038-1044, 1995等に記載の方法により、CTLクローンを樹立することもできる。
本発明のポリペプチドを有効成分として含有するCTL誘導剤をがん患者に投与すると、抗原提示細胞のHLA抗原に本発明のポリペプチドが提示され、HLA抗原と提示されたペプチドとの結合複合体特異的CTLが増殖してがん細胞を破壊することができ、その結果、がんを予防および/または治療することができる。したがって、本発明のポリペプチドを有効成分とするCTLの誘導剤は、好ましくは、HLA-A02抗原、HLA-A11抗原および/またはHLA-A24抗原陽性の対象に対して使用することができる。中でもより好ましくは、アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORISを発現するがんに罹患している対象、さらに好ましくはBORIS sf5および/またはsf6陽性のがんに罹患している対象に対して使用することができる。アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS陽性のがんとしては、例えば子宮頚部癌、卵巣癌、子宮癌、乳癌、大腸癌、肺癌、黒色腫等のがん(腫瘍)などが挙げられ、本発明のCTL誘導剤は、これらのがんの予防および/または治療のために使用することができる。特に、子宮頚部癌、卵巣癌、子宮癌などの女性特有の臓器におけるがん、および肺がんの予防および/または治療のために好ましく使用することができる。
本発明のポリペプチドを有効成分とするCTL誘導剤の剤形としては、特に限定はないが、油乳濁液(エマルション製剤)、高分子ナノ粒子、リポソーム製剤、直径数μmのビーズに結合させた粒子状の製剤、リピッドを結合させた製剤、マイクロスフェア製剤、マイクロカプセル製剤などが挙げられる。
以上述べたとおり、本発明のポリペプチドを有効成分として含有するCTL誘導剤を用いることにより、アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS陽性のがんを有効に処置することが可能である。したがって、本発明は一態様において、当該CTL誘導剤を有効成分として含む医薬組成物、好ましくはがん幹細胞処置用組成物、あるいはがんの予防および/または治療用組成物を含む。
本発明のポリヌクレオチドを発現させた細胞は、本発明のポリペプチドを抗原として提示する細胞となるため、T細胞受容体を介してT細胞に認識されるという特徴を有する。したがって、本発明のポリヌクレオチドもまたCTLの誘導剤となり得る。誘導されたCTLは、本発明のポリペプチドによって誘導されたCTLと同様に、細胞傷害作用やリンフォカインの産生を介して抗腫瘍作用、好ましくは抗がん作用を発揮することができる。従って本発明のポリヌクレオチドは、がんの治療または予防のための医薬や医薬組成物の有効成分とすることができる。本発明のポリヌクレオチドを有効成分として含有するCTLの誘導剤は、例えば、本発明のポリヌクレオチドをがん患者に投与し発現させることで、がんを治療および/または予防し得るものである。
本発明のポリヌクレオチドを有効成分とするCTLの誘導剤は、好ましくは、HLA-A02抗原、HLA-A11抗原および/またはHLA-A24抗原陽性の対象に対して使用することができる。中でもより好ましくは、アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORISを発現するがんに罹患している対象、さらに好ましくはBORIS sf5および/またはsf6陽性のがんに罹患した対象に対して使用することができる。アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS陽性のがんとしては、例えば子宮頚部癌、卵巣癌、子宮癌、乳癌、大腸癌、肺癌、黒色腫等のがん(腫瘍)などが挙げられ、本発明のCTL誘導剤は、これらのがんの予防または治療のために使用することができる。特に、子宮頚部癌、卵巣癌、子宮癌などの女性特有の臓器におけるがん、および肺がんの予防および/または治療のために好ましく使用することができる。
その他の方法としては、発現プラスミドを直接筋肉内に投与する方法(DNAワクチン法)、リポソーム法、リポフェクチン法、マイクロインジェクション法、リン酸カルシウム法、エレクトロポレーション法等が挙げられ、特にDNAワクチン法、リポソーム法が好ましい。また、発現プラスミドを、弱毒化したサルモネラ菌などの細菌に導入し、該細菌を投与して本発明のポリペプチドを発現させる細菌ベクター法も用いることができる。
当業者であれば、好適な細胞、ベクター、投与方法、投与形態および投与量を適宜選択することが可能である。
前記した本発明のポリペプチドまたはポリヌクレオチドは、がん患者の治療において、例えば、以下のようにin vitroで利用することができる。すなわち本発明のポリペプチドまたはポリヌクレオチドのいずれかと抗原提示能を有する細胞とを接触させることにより、抗原提示細胞を作製することができる。抗原提示細胞の作製は、in vitroで行われてもin vivoで行われてもよいが、好ましくはin vitroで行われる。具体的には本発明は、がん患者由来の単離された抗原提示能を有する細胞と、本発明のポリペプチドまたはポリヌクレオチドのいずれかを、好ましくはin vitroで接触させることにより、当該細胞の細胞表面に、例えばHLA-A02抗原やHLA-A11抗原、HLA-A24抗原などと本発明のポリペプチドとの複合体を提示させた抗原提示細胞、およびその製造方法を提供するものである。
本発明の抗原提示細胞には、例えば(1)適当な培養液中で、抗原提示細胞とCTLエピトープペプチドを30分から1時間混合したエピトープペプチドパルス抗原提示細胞、(2)CTLエピトープペプチドをコードする核酸を用い、遺伝子導入等で抗原提示細胞にCTLエピトープペプチドを提示させた細胞、(3)人工的に作製した抗原提示能を有する人工抗原提示細胞などが包含される。
ここで「抗原提示能を有する細胞」とは、本発明のポリペプチドを提示することの可能なMHC、好ましくはHLA-A02抗原、HLA-A11抗原および/またはHLA-A24抗原を細胞表面に発現する細胞であれば特に限定されないが、これらのうち、プロフェッショナル抗原提示細胞が好ましく、特に抗原提示能が高いとされる樹状細胞がより好ましい。人工的に作製した抗原提示能を有する人工抗原提示細胞は、例えば脂質2重膜やプラスティックあるいはラテックス等のビーズにHLAとCTLエピトープペプチドとβ2-ミクログロブリンとの3者複合体を固定し、CTLを刺激し得るCD80、CD83やCD86等の共刺激分子を固定するか、もしくは、共刺激分子と結合するT細胞側のリガンドであるCD28に対してアゴニスティックに作用する抗体等を固定することで作製可能である。
本発明の抗原提示細胞は、例えば、がん患者から抗原提示能を有する細胞を単離し、該細胞に本発明のポリペプチドをin vitroでパルスして、HLA-A02抗原、HLA-A11抗原および/またはHLA-A24抗原と本発明のポリペプチドとの複合体を提示させることにより得られる。樹状細胞を用いる場合は、例えば、がん患者の末梢血からフィコール法によりリンパ球を分離し、その後非付着細胞を除き、付着細胞をGM-CSFおよびIL-4存在下で培養して樹状細胞を誘導し、当該樹状細胞を本発明のポリペプチドと共に培養してパルスすることなどにより、本発明の抗原提示細胞を調製することができる。
また、前記抗原提示能を有する細胞に本発明のポリヌクレオチドを導入することにより本発明の抗原提示細胞を調製する場合は、当該ポリヌクレオチドは、DNAの形態であっても、RNAの形態であっても良い。ポリヌクレオチドを導入して抗原提示細胞を作成する方法は当該技術分野において知られており、当業者は適宜選択することができる。
本発明のポリペプチドおよびポリヌクレオチドは、がん患者の治療において、以下のように利用することができる。すなわち本発明のポリペプチドおよびポリヌクレオチドのいずれかと末梢血リンパ球とを接触させることにより、CTL、特にアイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS遺伝子を発現する細胞を特異的に認識するCTLを誘導することができる。すなわち本発明は、がん患者由来の末梢血リンパ球と、本発明のポリペプチドまたはポリヌクレオチドのいずれかを接触させることにより誘導されたCTL、およびその誘導方法を提供するものである。かかる方法は、in vitroで行われてもin vivoで行われてもよいが、好ましくはin vitroで行われる。
本発明のCTLを誘導する方法としては、具体的には例えば次の方法が挙げられる。まずPBMCあるいはT細胞を本発明のポリペプチドで直接刺激するか、該ペプチドをパルスした抗原提示細胞、遺伝子導入した抗原提示細胞、または人工的に作製した抗原提示能を有する人工抗原提示細胞で刺激する。刺激によって誘導されたCTLを5%CO2恒温槽にて37℃で7~10日培養する。CTLエピトープペプチドとIL-2、または抗原提示細胞とIL-2による刺激を週に1度繰り返す事で必要な細胞数のCTLを確保する。
HLA-テトラマーとは、HLAとβ2ミクログロブリンをペプチド(抗原ペプチド)と会合させた複合体(HLA-モノマー)をビオチン化し、アビジンに結合させることにより4量体化したものを指し(Science 279: 2103-2106(1998)、Science 274: 94-96 (1996))、例えば米国特許第5,635,363号、フランス特許出願公開第FR9911133号、米国特許第5,723,584号、米国特許第5,874,239号、米国特許第5,932,433号、米国特許第6,265,552号、特許登録第4976294号などに記載されている。現在では種々の抗原ペプチドを含有するHLA-テトラマーが作製されており、本発明のポリペプチドとHLA-A02、HLA-A11またはHLA-A24とを含有するHLA-テトラマーを容易に作製することができる。また、HLA-ダイマーおよびHLA-ペンタマーも同様な原理に基づいており、これらにおいては、それぞれ、前記HLAモノマーが2量体化および5量体化されている。したがって、本発明のポリペプチド、すなわちアイソフォームAまたはC、あるいはサブファミリー5または6に属するBORISのHLA結合能、とくにHLAクラスI結合能を有する部分ペプチドと、HLA-A02、HLA-A11またはHLA-A24とを含有するHLAモノマーおよびHLAマルチマー、特にHLA-テトラマーもまた、本発明の一態様である。
まずタンパク質を発現可能な大腸菌や哺乳動物細胞に、HLA-A24、HLA-A11あるいはHLA-A02の発現ベクターおよびβ2ミクログロブリン発現ベクターを導入し発現させる。ここでは大腸菌(例えばBL21)を用いることが好ましい。得られた単量体HLA-A24、HLA-A11あるいはHLA-A02複合体と本発明のポリペプチドとを混合し、可溶性のHLA-ペプチド複合体を形成させる。次にHLA-ペプチド複合体におけるHLA-A02、HLA-A11あるいはHLA-A24のC末端部位の配列をBirA酵素によりビオチン化する。このビオチン化されたHLA-ペプチド複合体と蛍光標識されたアビジンとを4:1のモル比で混合することにより、HLA-テトラマーを調製することができる。なお、前記各ステップにおいて、ゲルろ過等によるタンパク精製を行うことが好ましい。
(i)PBMCと、適当な濃度の本発明のHLA-テトラマーを反応させる。本発明のHLA-テトラマーと結合したCTLは標識色素により染色されるので、セルソーター、顕微鏡などを用いて染色されたCTLのみを単離する。このようにして単離されたCTLは、抗CD3抗体、PHA、IL-2等のT細胞刺激薬剤や、X線照射あるいはマイトマイシン処理等で増殖能を損失させた抗原提示細胞で刺激増殖させ、必要な細胞数を確保する。
(ii)本発明のHLA-モノマーおよび/またはテトラマーを無菌プレートなどに固相化し、PBMCを固相化プレートで培養する。プレートに固相化された本発明のHLA-モノマーおよび/またはテトラマーに結合したCTLを単離するためには、結合せずに浮遊している他の細胞を洗い流した後に、プレート上に残った特異的CTLだけを新しい培地に懸濁する。このようにして単離されたCTLは、抗CD3抗体、PHA、IL-2等のT細胞刺激薬剤や、X照射あるいはマイトマイシン処理等で増殖能を損失させた抗原提示細胞で刺激増殖させ、必要な細胞数を確保する。
(iii)本発明のHLA-モノマーおよび/またはテトラマーと、CD80、CD83、CD86等の共刺激分子か、もしくは、共刺激分子と結合するT細胞側のリガンドであるCD28に対してアゴニスティックに作用する抗体等を無菌プレートなどに固相化し、PBMCを固相化プレートで培養する。2日後にIL-2を培地に添加し5%CO2恒温槽にて37℃で7~10日培養する。培養した細胞を回収し新たな固相化プレート上で培養を続ける。この操作を繰り返す事で必要な細胞数のCTLを確保する。
本発明は、前述した本発明のHLA-テトラマーを利用した腫瘍の検出方法(検査方法、診断方法)もまた提供する。
本発明のHLA-テトラマーを用いる本発明の検出方法(診断方法)は、典型的には、被験者の血液を採取するか、若しくは腫瘍が疑われる被験組織の一部をバイオプシ等で採取し、そこに含まれるアイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS由来の腫瘍抗原ペプチドとHLA抗原との複合体を認識するCTLの量を、本発明のHLA-テトラマーによって検出・測定することにより、子宮頚部癌、卵巣癌、子宮癌、乳癌、大腸癌、肺癌、黒色腫等のアイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS陽性のがん(腫瘍)の罹患の有無またはその程度を検出、検査または診断するものである。特に、子宮頚部癌、卵巣癌、子宮癌などの女性特有の臓器におけるがん、または肺癌の罹患の有無またはその程度を検出、検査または診断することができる。
本発明の検出(検査、診断)方法は、例えば腫瘍を有する患者において、該腫瘍の改善のために治療薬を投与した場合における、該腫瘍の改善の有無またはその程度を検出(検査、診断)することもできる。さらに本発明の検出(検査、診断)方法は、本発明のポリペプチドまたはポリヌクレオチドを有効成分とする医薬を有効に適用できるがん患者の選択や、当該医薬による治療効果の予測や判定などにも利用できる。
(a)被験者から得られた生体試料と本発明のHLA-テトラマーとを接触させる工程、
(b)該生体試料中のBORIS sf5またはsf6由来の腫瘍抗原ペプチドとHLA抗原との複合体を認識するCTLの量を、上記HLA-テトラマーが結合した細胞の量を指標として測定する工程、
(c)(b)の結果をもとに、がんの罹患を判断する工程。
本発明のHLA-テトラマーを用いる本発明の診断方法の特定の態様は、上記(a)、(b)および(c)の工程を含む。
ここで被験者の被験組織と正常な対応組織との前記レベルの比較は、被験者の生体試料と正常者の生体試料を対象とした測定を並行して行うことで実施できる。並行して行わない場合は、複数(少なくとも2つ、好ましくは3以上、より好ましくは5以上)の正常な組織を用いて均一な測定条件で測定して得られた本発明のポリペプチド特異的CTLの量の平均値または統計的中間値を、正常者の値すなわち基準値として、比較に用いることができる。
本発明はまた、対象におけるがんを予防および/または治療する方法であって、本発明のポリペプチド、ポリヌクレオチド、CTL、抗原提示細胞からなる群から選択される有効成分の有効量を、それを必要とする対象に投与する工程を含む方法にも関する。
本発明における「対象」は、任意の生物個体を意味し、好ましくは動物、さらに好ましくは哺乳動物、さらに好ましくはヒトの個体である。本発明において、対象は健常であっても、何らかの疾患に罹患していてもよいものとするが、がんの予防および/または治療が企図される場合には、典型的にはがんに罹患しているか、罹患するリスクを有する対象を意味する。本発明の一態様において、対象はHLA-A02陽性、HLA-A11陽性および/またはHLA-A24陽性である。本発明の一態様において、対象はアイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS陽性のがんに罹患しているか、罹患するリスクを有する。本発明の一態様において、対象はHLA-A02陽性、HLA-A11および/またはHLA-A24陽性であり、かつ、アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS陽性のがんに罹患しているか、罹患するリスクを有する。
本明細書中で言及する全ての特許、出願および他の出版物は、その全体を参照により本明細書に援用する。
本発明はまた、アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORISの少なくとも一部、好ましくは配列番号1、配列番号2または配列番号76で表されるポリペプチドの少なくとも一部、より好ましくは配列番号1または配列番号2で表されるポリペプチドの少なくとも一部と特異的に結合する抗体もまた提供する。したがって本発明の抗体は、好ましくはサブファミリー5または6に属するBORISを特異的に認識することができる。抗体は、ポリクローナル抗体であってもモノクローナル抗体であってもよいが、好ましくはモノクローナル抗体である。
また、本発明の抗体にはFab、Fab’、F(ab’)2、Fv、scFv、dsFv、Diabodyおよびsc(Fv)2などの、抗体の機能的断片も含まれる。また、これら機能的断片の多量体(例えば、ダイマー、トリマー、テトラマー、ポリマー)も、本発明の抗体に含まれる。
本発明の抗体は、アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORISに対して特異的に結合可能な抗体であり、アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORISを発現する細胞を検出したり、アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS自体を検出したりすることが可能である。したがって本発明の一態様において、本発明の抗体を含むBORISタンパク質の検出用キットおよび/または精製用キットが提供される。
本発明のキットは、本発明の抗体以外に、1または2以上のキットの用途に適した任意の構成部品をさらに含んでよく、かかる構成部品としては、これに限定するものではないが、例えば標識されていてもされていなくてもよい二次抗体、発色試薬、溶媒、緩衝液、陽性コントロール、陰性コントロール、反応容器、前処理試薬、ブロッキング試薬、スライドガラス、カバーガラス、各用途についての取扱説明書などが挙げられる。
本発明は、子宮頚部癌や卵巣癌中の幹細胞性の性質を有する細胞において、BORISタンパク質、特にBORIS sf5および/またはsf6が高発現しているという知見に基づくものである。したがって、かかる知見に基づく様々な技術が本発明に包含される。
本発明は、一態様において、BORIS sf5またはsf6を特異的に認識する抗体に関する。かかる抗体は、配列番号1または2に記載のアミノ酸配列を有するポリペプチドまたはその一部をエピトープとして認識するように、当該技術分野において知られた方法を用いて作製することができる。かかる抗体を用いることにより、例えば特定の組織および/または細胞におけるBORIS sf5および/またはsf6の発現量を検出することが可能であり、それによって組織や対象におけるがん幹細胞や腫瘍の存在の有無を判定することが可能である。また、かかる抗体を用いてがん幹細胞の幹細胞性に影響するBORIS sf5および/またはsf6の機能を抑制することにより、がん幹細胞を処置すること、がんの予防および/または治療を行うことが可能である。
本発明のさらに別の一態様において、対象から得られた試料におけるBORIS sf5および/またはsf6のmRNAおよび/またはポリペプチドのレベルを検出すること、および正常組織および/または細胞におけるBORIS sf5および/またはsf6のmRNAおよび/またはポリペプチドのレベルを基準値として、前記検出されたレベルと前記基準とを比較することを含む、がん幹細胞の検出方法に関する。mRNAおよび/またはポリペプチドのレベルを検出する方法としては、当該技術分野において知られた方法を用いてよい。mRNAのレベルを検出する方法としては、例えばRT-PCR、DNAマイクロアレイ、ノーザンブロッティングなどが挙げられる。かかるmRNAのレベルを検出する方法において、上記BORIS sf5および/またはsf6のプライマーおよび/またはプローブを用いてよい。ポリペプチドのレベルを検出する方法としては、例えば免疫組織染色、ウェスタンブロッティングなどが挙げられる。かかるポリペプチドのレベルを検出する方法において、上記BORIS sf5および/またはsf6の特異的抗体を用いてよい。
以下に実施例を示し、本発明を具体的に説明するが、本発明はこれらに限定されるものではない。特に断りがない限り、実験法は、例えば「免疫実験操作法」、編集:右田俊介、紺田進、本庶佑、濱岡利之、に記載の方法など、当該技術分野において通常用いられる方法を用いた。
また、以下の実施例において用いたBORISのアイソフォームおよびサブファミリーを以下の表に示す。特段の記載のない限り、アイソフォーム名が記載されている場合は特定のアイソフォームを意味し、サブファミリー名が記載されている場合はサブファミリーに属するアイソフォームのいずれかを意味し、単に「BORIS」と記載した場合はアイソフォームやサブファミリーを特定しない一般的なBORIS遺伝子の発現産物か、またはBORIS B0アイソフォームのことを意味するものとする。また以下の実施例において、「ペプチド名-Tet」は、ペプチド名で表されるペプチドと結合したHLAテトラマーを意味する。
(1)スフェロイド形成細胞の単離
子宮頚部癌においては、がん幹細胞マーカーの指標の一つとしてスフェア形成が報告されている。そこで、低接着性培養皿を用いたスフェロイド形成アッセイを行った。超低接着性表面を有するマルチウェルプレート(Ultra Low Attachment 6-well plate、Corning社製)を用いて各子宮頚部癌細胞株(CaSki、TCS、MS751、SKG-IIIb、ME-180およびSiHa)を培養した。細胞は、接着培養したものを2mMのEDTAに0.25%のトリプシンを加えた溶液で剥離し、各ウェルに103個/ウェルとなるように播種した。培地として、無血清DMEM/F-12培地に20ng/mlのh-EGF(R&D systemsより入手)、10ng/mlのb-FGF(R&D systemsより入手)、1%のペニシリン/ストレプトマイシン(GIBCOより入手)、4μg/mlのヘパリン、および終濃度1%のN2サプリメント(WAKOより入手)を加えたものを用い、通常の培養条件で7日または14日間培養し、全ての細胞株において100μm以上のスフェロイドの形成が確認された(図1)。以下の試験において、「スフェア(sphere)」と表示されている細胞群は、本試験と同様の非接着培養により形成されるスフェロイドから単離された細胞群を意味する。また、「バルク(bulk)」と表示されている細胞群は、通常の接着培養により得られる細胞群を意味する。
スフェロイド形成細胞が幹細胞様の性質を示す細胞であることを確認するために、放射線耐性試験、抗癌剤耐性試験、フローサイトメトリー分析を行いスフェア群がバルク群と比較して、より幹細胞様の性質を示す群であることを確認した。
幹細胞性遺伝子としてSOX2、NANOGおよびOct3/4を用い、CaSkiおよびTCS細胞株のバルク群およびスフェア群における前記各遺伝子の発現量について、定量的RT-PCRでそれぞれ解析した。PCR機器はSTEPONE realtime PCR system(Applied Biosystems社製)を使用し、遺伝子の発現はthreshold cycle number(Ct)で検出し、ΔΔCt法でバルク群における幹細胞性遺伝子の発現を1とした場合の相対発現量を定量した。SOX2、NANOG、Oct3/4のプライマー・プローブミックスはTaqMan gene expression (Applied Biosystems)を使用した。
結果を図2に示す。どちらの細胞株においても、スフェア群の細胞において幹細胞性遺伝子が高発現していることがわかる。これは、スフェア群に幹細胞様の性質を示すがん細胞が濃縮されていることを示唆している。特に顕著に幹細胞性遺伝子を発現していたCaSki細胞株を用いて、下記cDNAマイクロアレイ解析を行った。
バルク群と比較してスフェア群において高度に発現している遺伝子について解析するために、cDNAマイクロアレイを行った。まず、市販のアミノアリルRNA増幅キットver2(高収率タイプ)(Sigma Aldrich)を用いて、キットに付属の説明書に従って、各細胞より全RNAを抽出した。得られた全RNA 3μgを市販のオリゴdT T7プロモータープライマーおよび逆転写酵素を用いて逆転写し、cDNAを合成した。次にT7RNAポリメラーゼを用いてcRNAを合成し、同時にCy3またはCy5標識シチジントリホスフェートを取り込んだ。このプロセスにより、スフェア群細胞のサンプルをCy5で標識し。バルク群細胞のサンプルをコントロール細胞としてCy3で標識した。再度cRNAの質を、NanoDrop(Thermo Scientific社)を用いて確認した。その後Cy3標識cRNAおよびCy5標識cRNAと組み合わせ、ハイブリダイゼーションカクテル(Sigma Aldrich)中で断片化した。標識化されたcRNAを60merプローブオリゴヌクレオチドマイクロアレイ(Panorama Human Micro Array、Sigma Aldrich)にハイブリダイズさせ、50℃で20時間インキュベートした。蛍光強度を、Genepix 4000B Microarray Scanner(Axon Instruments社)を用いて決定した。同様の方法で、スフェア群細胞のサンプルをCy3で標識し、バルク群細胞のサンプルをCy5で標識して再度実験を行った(Dye Swap法)。
上記cDNAマイクロアレイの結果において、がん・精巣抗原(CT抗原)を対象として、スフェア群における発現を確認した。結果を下表に示す。
(1)正常組織におけるBORISの発現解析
正常組織のcDNAライブラリーとして、Human Multiple Tissue cDNA Panels I and II(Clontech社)を用いた。PCRは0.1~0.5μlのcDNA、0.1μlのTaq DNA polymerase(Qiagen社)および12pmolのプライマーを含むcDNAミクスチャを、まず94℃で2分間温めた後、続いて94℃で15秒解離、60℃で30秒アニーリング、68℃で30秒伸長のサイクルを30~40サイクル行った。プライマーは配列番号35および36を用いた。
結果を図3に示す。BORISは正常組織においては、精巣以外にはほとんど発現していないことがわかる。
子宮頚部癌細胞株としてMS751、TCS、CaSki、SKG-IIIb、ME-180およびSiHaを用い、各細胞株のバルク群およびスフェア群から上記例1(4)と同様の方法を用いてcDNAを採取し、各細胞株におけるBORISの発現量を、例1(3)と同様の方法で、TCS細胞株のバルク群における発現を1とした場合の相対発現量を定量した。BORISのプライマー・プローブミックスはTaqMan gene expression (Applied Biosystems)を使用した。
結果を図4に示す。半数以上の細胞株において、バルク群に比べてスフェア群でBORISの発現量が大幅に増大していた。
子宮体癌細胞株としてRL95-2およびHEC-1-A、卵巣癌細胞株としてTOV-21G、ES-2、MCAS、Ovcar-3、SMOV-2およびSKOV-3のバルク群細胞におけるBORISの発現量を、(2)と同様にTCSのバルク群細胞における発現量を1とした相対発現量として定量した。
結果を図5に示す。BORISは子宮頚部癌だけでなく、子宮体癌や卵巣癌においても高い発現量を示した。
子宮頚部癌細胞株におけるBORISの各サブファミリーのアイソフォームの発現量を、(1)と同様にRT-PCRにて解析した。各サブファミリーに特異的なプライマーとして下表のプライマーを用いた。
上記(4)と同様の実験を、子宮頚部癌細胞株CaSkiおよびMS751に代えて、卵巣癌細胞株TOV21GおよびSMOV-2を用いて行った。結果を図7に示す。
上記子宮頚部癌細胞株の結果と同様、卵巣癌細胞株においても、スフェア群細胞においてBORIS sf6の特異的発現が観察された。また、卵巣癌細胞株においては、どちらの細胞株でもsf6のみならずsf5の発現もバルク群細胞に比較して顕著に上昇していた。
上記(5)と同様の実験を、小細胞肺癌、非小細胞肺癌、肺扁平上皮癌、肺腺癌由来の細胞株、および肺がん患者手術切除片から樹立した初代培養細胞を用いて行った。スフェロイド形成細胞は、N2サプリメントおよびヘパリンを加えない培地を用いた以外は上記例1(1)と同様の手順を用いて調製した。結果を図19-1、図19-2、図19-3、図19-4および図19-5に示す。
肺癌由来の細胞株でもBORIS遺伝子の発現が認められた。具体的には、図19-1の小細胞肺癌株では、SBC1とSBC5でBORIS sf5がスフェア群で発現増強しており、Lc817ではsf6の発現増強が観察された。図19-2ではBORIS sf5やsf4aの発現が確認され、同様に肺扁平上皮癌や肺腺癌でのBORISの発現もしくはスフェア群での発現増強が観察された。さらに図19-5に示すように、肺がん患者手術切除片から樹立した初代培養細胞においてもBORISの発現が確認されており、特にPrimary7細胞ではスフェア群において幾つかのsfでの発現増強が確認されることから肺癌においてもBORISががん免疫療法の非常に有望な抗原になり得ることが示された。
(1)BORISアイソフォームの過剰発現株の作製
pMXpuroベクターおよびPlat-A細胞を含む、Platinumレトロウイルス発現システムを用いて、BORISのsf1アイソフォームであるB0アイソフォーム、sf4アイソフォームであるB3アイソフォーム、sf6アイソフォームであるB6アイソフォームおよびC7アイソフォームをコードするレトロウイルスベクターを作製し、TCS細胞株に導入してそれぞれのBORISアイソフォームの過剰発現株を作製した。BORISアイソフォームの発現量を定量的PCRで確認したところ、それぞれmockベクターを導入したものと比較して約1万倍の発現を確認した。同様の方法により、SKG-IIIb細胞株に導入した過剰発現株も作製した。
上記例1(1)と同様の方法で、1000個/ウェルの過剰発現TCS細胞株および過剰発現SKG-IIIb細胞株を播種して、2週間の培養によりスフェア形成アッセイを行った。
結果を図8および図9に示す。どちらの細胞株においても、BORIS sf6、特にBORIS B6アイソフォームの大量発現株において有意なスフェア形成が確認された。
HLAクラスI分子と結合して抗原提示されるエピトープペプチドは、8~10個のアミノ酸からなり、N末端側から2番目と、9あるいは10番目のアミノ酸はHLAクラスI分子との結合に対して最も重要なアミノ酸であり、アンカーモチーフと呼ばれている。このアンカーモチーフは、各々のHLAクラスI分子の種類によって異なることが報告されている。例えば、世界的に最も研究が進められているHLA-A2分子に結合するエピトープペプチドは、N末端より2番目の位置にロイシンを有し、9あるいは10番目の位置にロイシンまたはバリンを有する、9~10個のアミノ酸からなるペプチドが最も良く知られている。また、HLA-A24分子に結合するペプチドとしては、N末端より2番目の位置にチロシン、フェニルアラニン、メチオニンまたはトリプトファンのいずれかを有し、9あるいは10番目の位置にロイシン、イソロイシン、トリプトファンまたはフェニルアラニンのいずれかを有する、9~10個のアミノ酸からなるペプチドが最もよく知られている。
T2細胞を、26℃で一晩培養した。その後細胞をPBSで洗浄し、HLA-A2結合性ペプチド候補として(3)で合成したKLLペプチドおよびLLFペプチド、ポジティブコントロールとしてサイトメガロウィルス由来のペプチドであるCMVペプチド(配列番号37)およびインフルエンザウィルス由来のペプチドであるInfluenza(配列番号38)、ならびにネガティブコントロールとしてHLA-A24結合性ペプチドであるGK-12ペプチド(配列番号39)を加えて、26℃で3時間共培養した。温度を37℃にしてさらに3時間共培養した後、遠心分離して上清を除き、細胞を単離した。単離した細胞にHLA-A2抗体を加え、4℃で1時間静置し、その後PBSで洗浄した。2次抗体として蛍光標識抗マウスIgG+IgM抗体を加え、4℃で30分静置した後、1%ホルマリンを加えて細胞を固定した。固定した細胞を、フローサイトメーター(BECTON DIKINSON社またはBeckman Coulter社)にて、FITC蛍光強度を計測した。
HLA-A*02:01を保持していることがわかっている健康な成人2名から末梢血を採取し、3,000rpmで5~10分間遠心処理して上清の血漿部分を回収した。血漿部分以外から、密度勾配遠心法にてPBMCを分離した。96ウェルU底細胞培養用マイクロテストプレート(BECTON DIKINSON社)の各ウェルに、Hepes改変RPMI1640培地(Sigma社)に2-メルカプトエタノール(最終濃度55μM)、L-グルタミン(最終濃度2mM)、抗生物質としてストレプトマイシン(最終濃度100μg/mL)とペニシリンG(最終濃度100U/mL)および5%の血漿成分を加えた培地を10mLおよび上記で分離したPBMCを約3×107個/プレート入れ、浮遊させて培養した。これに10μg/mLの濃度で配列番号4または、配列番号5のBORIS sf6特異的CTLエピトープ候補ペプチドを加えた。2日間培養後、50U/mLの最終濃度でIL-2を添加し、さらに2週間培養した。
KLLペプチド特異的CTLの頻度
=(HLA-テトラマー試薬陽性ウェル数)/(実験に用いたPBMCの数×誘導前のCD8陽性率)
=2/(3×107×0.16)
=4.17×10-7
LLFペプチド特異的CTLの頻度
=(HLA-テトラマー試薬陽性ウェル数)/(実験に用いたPBMCの数×誘導前のCD8陽性率)
=19/(3×107×0.17)
=3.73×10-6
HLA-A*02:01を保持していることがわかっている健康な成人3名から末梢血を50mL採取し、遠心処理して上清の血漿部分を回収した。血漿を除いた後の血球部分から、リンフォプレップ(Axis-Shield Pros As社)を用いて、PBMCを分離した。分離したPBMCは、10mLのAIM-V培養培地に懸濁し、細胞培養用ディッシュに播種し、37℃のCO2インキュベーターの中で、4時間培養した。AIM-V培養培地はライフテクノロジーズ社のAIM-Vに、終濃度10mMのHEPES(ライフテクノロジーズ社)、終濃度50μMの2-メルカプトエタノール(ライフテクノロジーズ社)を添加した培地を意味する。その後、浮遊細胞のみを回収し、MACSビーズ(ミルテニーバイオテク社)を使用し、磁気細胞分離法を用いてCD8陽性細胞と陰性細胞を分離した。
上記培養を開始した同日に、CD8陰性細胞の一部のウェルに終濃度1μg/mLのPHA(phytohemagglutinin、Wako社)、終濃度100U/mLのIL-2(ライフテクノロジーズ社)を添加した。培養開始から4日目、カルチャーチューブ(BD社)に細胞を回収し、10mLのAIM-V培養培地に懸濁し、75cm2培養フラスコ(ヌンク社)に入れた。さらに、終濃度100U/mLのIL-2(シオノギ社)を添加した。培養開始から8日目、細胞をカルチャーチューブ(BD社)に回収し、1mLのAIM-V(ライフテクノロジーズ社)に懸濁し、配列番号5のペプチド(最終濃度20μg/mL)を添加した。その後、室温にて1時間放置し、100Gyの放射線照射処置を行い、PHAブラスト細胞を調製した。
培養開始から8日目、各ウェルにIL-7(R&Dシステムズ社)を10ng添加した。さらに、CD8陽性細胞とPHAブラスト細胞が5対1となるように混合し、共培養を開始した。培養開始から9日目、16日目にPHAブラスト細胞の調製を再度開始し、PHAブラスト細胞の調製が完了する16日目、23日目にCD8陽性細胞とPHAブラスト細胞が5対1となるように再度混合し、PHAブラスト細胞による刺激を合計3回行った。培養開始16日目にIL-2(シオノギ社)を10U/mL添加し、段階的に濃度を上げ、最終的に50U/mLまで濃度を上げ、28日目まで培養を継続した。
BOIRS特異的CTLの機能解析は、ELISPOT Set(BD社)キットを用いて行った。まず、BORIS sf6特異的CTLを誘導した細胞集団の一部を採取して、5×105個/mLに調製した。このサンプルを、抗IFNγ抗体が固相されたELISPOSTアッセイ用プレートに100μL/ウェルで撒き、37℃のCO2インキュベーターの中で、30分静置した。そのプレートに、T2細胞に配列番号5のペプチドをパルスした細胞を5×104個/ウェルとなるように添加し、37℃のCO2インキュベーターの中で、一晩静置した。洗浄後、ビオチン標識抗IFNγ抗体を加え、室温にて2時間反応した。反応液を洗い、HRP標識ストレプトアビジンを加え反応させた。洗浄後、発色剤を100μL/ウェル加え、15~30分反応することにより、CTLが分泌したIFNγをスポット化して測定した。
上記(7)でIFNγの産生能を確認したBORIS sf6特異的CTLを、HLA-テトラマー試薬と抗CD8-FITC(MBL社)抗体で二重染色し、HLA-テトラマー試薬および抗CD8-FITC抗体と反応した細胞をフローサイトメーターで96ウェルプレート(コーニング社)に1細胞ずつ播種した。この細胞を培養する培地は、AIM-V培養培地に終濃度10%のヒトAB血清(ロンザジャパン社)、終濃度1%のペニシリン/ストレプトマイシン(ライフテクノロジーズ社)、終濃度1%のGlutaMAX(ライフテクノロジーズ社)、終濃度100U/mLのIL-2(シオノギ社)、終濃度5μg/mLのPHA(Wako社)を添加したものを用いた。各ウェルには、健康な3人のドナーから採血し分取したPBMC50000個に、100Gyの放射線照射措置した細胞を添加した。
また、フローサイトメーターで単離した細胞は、培地の色を観察して随時、半分量の培地交換を行った。さらに、細胞が増えた段階で、48ウェルプレートに移し替えた。
(8)で培養を終えたLLFペプチド特異的CTLがLLFペプチドを提示する細胞を攻撃するかを、LDH killingアッセイ(TaKaRa Bio社)で解析した。まず、LLFペプチド特異的CTLの攻撃の対象となる標的細胞(Target)を調製した。T2細胞に配列番号5のLLFペプチドをパルスした細胞とそのネガティブコントロールとして、HIV由来ペプチド(SLYペプチド)をT2細胞にパルスした細胞、T2細胞のみの3種類の細胞を準備した。標的細胞は、96ウェルV底プレート(コーニング社)に、1×104個/ウェルずつ撒いた。LLF特異的CTL(Effector)は、9×105個/mL、3×105個/mL、1×105個/mLの濃度の細胞懸濁液を調製し、1ウェル100μLずつ撒き、96ウェルプレートに撒いた標的細胞と混合した。その後、96ウェルプレートを、1800rpm、10分遠心後、37℃のCO2インキュベーターの中で4時間から12時間静置した。96ウェルプレートを遠心し、細胞を沈殿させた後、上清100μLを平底96ウェルプレートに移した。それぞれのウェルに、diaphoraseを含む反応液を100μL加えて室温で30分静置し、そののち490nmの吸光度を測定した。この操作により、通常は細胞膜内に存在するLDHが、細胞が傷害を受けている場合細胞膜の損傷により細胞外に放出されるため、培養液中のLDH量を測定することにより細胞傷害性を査定することが可能である。この方法を用いて、LLFペプチド特異的CTLが、LLFペプチドを提示する標的細胞を認識し攻撃するかを検討した。
LLFペプチド特異的CTLは、ネガティブコントロールのHIV由来ぺプチド(SLYペプチド)をパルスしたT2細胞を標的細胞とした場合、またはペプチドを加えていないT2細胞を標的細胞とした場合と比較して、LLFペプチドをパルスしたT2細胞を標的細胞とした場合に高い割合で細胞傷害性活性を示した。すなわちLLFペプチド(配列番号5)が提示されたがん細胞を特異的に認識し細胞傷害性活性を発揮することが明らかとなった。
(1)BORIS特異的HLA結合性エピトープ候補の抽出
上記例3(3)と同様に、BORIS特異的なHLA結合性エピトープ候補を抽出した。分析対象のBORISとしては、最も長いアミノ酸配列を有し、かつがん幹細胞に特異的に発現しているBORISの候補でもあるBORIS B1アイソフォーム(サブファミリー5)を用い、日本人の約60%が保持するHLA-A*24:02に対して結合性を有するエピトープの候補を抽出し、合成した。合成したペプチドを以下に示す。
HLA-テトラマー試薬製造の最初のステップは、原料であるHLAとβ2-ミクログロブリンとペプチドを試験管内の適切な溶液中で混合するフォールディングから始まる。フォールディング溶液中では、この3種類の原料の会合反応により3者複合体(HLA-モノマー)を形成する。この際、HLAとペプチドの結合力が高ければ、この会合反応はスムーズに進行し、ゲル濾過カラムで分析する事で、3種類の原料の複合体(HLA-モノマー)の検出が可能になる。一方、HLAとペプチドの結合力が無い場合は、HLA-モノマーは殆ど検出されない。従って、フォールディング溶液を経時的に分析する事で、或いは熱処理等を行う事で、HLAとペプチドの結合性と安定性を検証する事が可能である。本明細書においては、この試験を「フォールディングテスト」という。
上記合成した11種類のペプチドを用いてフォールディングテストを実施した。簡潔には、大腸菌発現系を利用して発現精製したHLA-A*24:02(60mg/L)、β2-ミクログロブリン(20mg/L)、およびBORIS特異的CTLエピトープ候補ペプチド(30μM)をフォールディング溶液(1MのTris-HCl、0.5MのEDTA、2Mのアルギニン、5mMのGSH、0.5mMのGSSGおよびプロテアーゼ阻害剤)に添加(括弧内の濃度はいずれも終濃度)して混合後、経時的にフォールディング溶液を分取し、ゲル濾過カラムにて分析を行った。9個のアミノ酸からなる陽性コントロールペプチド(配列番号40)と、10個のアミノ酸からなる陽性コントロールペプチド(配列番号41)、およびそれぞれの陰性コントロール(配列番号42および43)を比較対象に用いた。
上記(2)のフォールディングテストの結果に基づき、配列番号11以外の10種のBORIS特異的CTLエピトープ候補ペプチドとHLA-A*24:02を用いてPE標識HLA-テトラマー試薬を製造した。本明細書において、製造したHLA-テトラマー試薬は例えばKYA-Tetなどの略号で示すが、これは、HLA-A*24:02とペプチドKYA(KYASVEASKL)とβ2-ミクログロブリンの3者複合体を用いて製造されたものを示す。簡潔には、上記(2)と同様に、HLA-A*24:02とβ2-ミクログロブリン、およびBORIS特異的CTLエピトープ候補ペプチドをフォールディング溶液に添加して混合し、HLA-モノマーを形成させた。ここで、組換えHLA-A*24:02分子のC末端側にビオチン結合部位が付加されるように発現タンパク質を設計しておき、HLA-モノマー形成後、当該部位にビオチンを付加した。色素標識されたストレプトアビジンおよび上記ビオチン化HLA-モノマーをモル比1:4で混合し、HLA-テトラマー試薬を得た。
HLA-A*24:02を保持していることがわかっている健康な成人7名から末梢血を採取し、3,000rpmで5~10分間遠心処理して上清の血漿部分を回収した。血漿部分以外から、密度勾配遠心法にてPBMCを分離した。96ウェルU底細胞培養用マイクロテストプレート(BECTON DIKINSON社)の各ウェルに、Hepes改変RPMI1640培地(Sigma社)に2-メルカプトエタノール(最終濃度55μM)、L-グルタミン(最終濃度2mM)、抗生物質としてストレプトマイシン(最終濃度100μg/mL)とペニシリンG(最終濃度100U/mL)および5%の血漿成分を加えた培地を10mLおよび上記で分離したPBMCを約3×105個/ウェル入れ、浮遊させて培養した。これに10μg/mLの濃度で配列番号11以外の上記BORIS特異的CTLエピトープ候補ペプチドを加えた。2日間培養後、50U/mLの最終濃度でIL-2を添加し、さらに2週間培養した。
解析は2段階で行った。まず1段階目は、96ウェルU底細胞培養用マイクロテストプレートの縦列の8ウェル分の細胞を1サンプルとして回収し、このサンプル中のBORIS特異的CTLの誘導の有無を確認した。この段階でCTL誘導が確認されたサンプルについて、2段階目の解析を行った。2段階目は、1サンプルとした8ウェルから個別に細胞を回収し、BORIS特異的CTLの誘導の有無を確認した。
RMMペプチド特異的CTLの頻度
=(HLA-テトラマー試薬陽性ウェル数)/(実験に用いたPBMCの数×誘導前のCD8陽性率)
=5/(3×107×0.18)
=9.26×10-7
Kuzushima et al., Clin Exp Immunol. 1996;103:192-198に記載の方法にしたがって、EBV感染B細胞株(以下EBV感染LCLと称する)を樹立した。簡潔には、EBV産生細胞株であるB95-8細胞(JCRB Cell Bankより入手)の培養上清(生EBVウイルスを含む)とPBMCを混合培養してEBV感染LCLを得た。
(4)で誘導したPBMCの1/2量を96ウェルU底細胞培養用マイクロテストプレートに移し、RMMペプチドを最終濃度100ng/mLとなるように加えた。さらにブレフェルジンA(BFA)を最終濃度1μg/mLとなるように加え、5%CO2恒温槽にて37℃で5~16時間培養した。培養後、細胞を洗浄し、PE(フィコエリスリン)標識HLA-テトラマー試薬とPC5(フィコエリスリン-Cy5)標識CD8抗体(Beckman Coulter社)を加え、室温にて15~30分放置した。洗浄後、4%ホルムアルデヒドにて、4℃、15分固定後、過剰量の洗浄液にて洗った。0.1%サポニンにて膜透過処理後、FITC標識抗IFNγ抗体(MBL社製)を加え、室温にて15~30分反応させた。洗浄後、フローサイトメーターを用いて、T細胞中のIFNγ陽性細胞率あるいはHLA-テトラマー試薬陽性細胞中のIFNγ陽性細胞率を定量した。
PHAブラスト細胞の調製の際に配列番号10のペプチド(RMMペプチド)を用いた以外は例3(6)と同様の手順を用いて、HLA-A*24:02または、HLA-A*02:01を保持していることがわかっている健康な成人からBORIS sf5特異的なCTLの誘導をおこなった。
RMMペプチドは、BORIS B1アイソフォームの670~678番目のアミノ酸である。ここで、BORIS B1はBORISのサブファミリー5に属する、700アミノ酸からなるアイソフォームであり、BORIS sf5はC末端側の132アミノ酸、とくにC末端側38アミノ酸(配列番号2)にサブファミリー特異的配列を有することが知られていることから、RMMペプチドはBORIS sf5に特異的な配列であり、本発明によりBORIS sf5を特異的に発現することが見いだされた卵巣癌由来のがん幹細胞も標的にすることができるCTLを誘導可能なエピトープペプチドである。
(1)BORIS特異的HLA結合性エピトープ候補の抽出
分析対象のBORISとしては、BORIS C1アイソフォーム(サブファミリー1、配列番号76)を用い、HLA型としてHLA-A*02:01を用いた以外は例3(3)と同様にして、BORIS特異的なHLA結合性エピトープ候補を抽出した。合成したペプチドを以下に示す。
表7のとおり合成した11種類のペプチドを用いてフォールディングテストを実施した。フォールディングテストは、HLAとしてHLA-A*02:01を用い、エピトープ候補ペプチドとして上記表7に記載のものを用い、陽性コントロールペプチドに配列番号58のペプチドおよび陰性コントロールに配列番号59のペプチドを比較対象として用いたこと以外は、例4(2)と同様の方法を用いて行った。
(2)のフォールディングテストの結果に基づき、配列番号55を除く、配列番号47から配列番号57の10種類のBORIS特異的CTLエピトープ候補ペプチドとHLA-A*02:01を用いた以外は例4(3)と同様の手順にてPE標識HLA-テトラマー試薬を製造した。
HLA-A*02:01を保持していることがわかっている健康な成人4名を対象とし、配列番号55を除く、配列番号47から配列番号57のBORIS特異的CTLエピトープ候補ペプチドを用いた以外は例3(5)と同様の方法でCTLの誘導を行った。
VLEペプチド特異的CTLの頻度
=(HLA-テトラマー試薬陽性ウェル数)/(実験に用いたPBMCの数×誘導前のCD8陽性率)
=1/(3×107×0.18)
=1.85×10-7
KLAペプチド特異的CTLの頻度
=(HLA-テトラマー試薬陽性ウェル数)/(実験に用いたPBMCの数×誘導前のCD8陽性率)
=3/(3×107×0.19)
=5.26×10-7
VLTペプチド特異的CTLの頻度
=(HLA-テトラマー試薬陽性ウェル数)/(実験に用いたPBMCの数×誘導前のCD8陽性率)
=2/(3×107×0.19)
=3.51×10-7
検体A2-29から誘導したKLAペプチド特異的CTL含むPBMCまたは、検体A2-29から誘導したVLTペプチド特異的CTLを含むPBMCを96ウェルU底細胞培養用マイクロテストプレートに、約3×106個となるように各2ウェル分移した。KLAペプチド特異的CTLを含むPBMCにはKLAペプチド、VLEペプチド特異的CTLを含むPBMCには、VLEペプチドを最終濃度100ng/mLとなるように2ウェルのうち、1ウェル分に加え、もう1ウェルは未処理のウェルとして準備をした。さらに、抗CD107a-FITC標識抗体とモネンシンをペプチド添加ウェル、未処理ウェルともに加え、37℃のCO2インキュベーターの中で、4時間培養した。培養後、細胞を洗浄し、それぞれのペプチドに対応したPE標識HLA-テトラマー試薬とPC5(フィコエリスリン-Cy5)標識抗CD8抗体(Beckman Coulter社)を加え、室温にて15~30分放置した。過剰量の洗浄液にて洗い、フローサイトメーターを用いて、CTLの脱顆粒マーカーであるCD107aを検出し陽性細胞率を算出した。CTLは、パーフォリン、グランザイムなどの細胞傷害性因子を放出する際に、細胞内顆粒内膜に存在するCD107aを細胞膜上に表出することが知られており、CD107a分子を検出することで、細胞傷害因子の放出を間接的に調べることができる。
上記例3(3)と同様に、BORIS特異的なHLA結合性エピトープ候補を抽出した。ただし、日本人を含む東南アジアでは第3位の保有率を示すHLA-A*11:01に結合性を有するエピトープの候補を抽出した点のみ異なる。抽出したエピトープ候補のペプチド配列を合成し、その配列を表9-1に示し、コントロールペプチドを表9-2に示す。
表9-1のとおり合成した13種類のペプチドを用いてフォールディングテストを実施した。フォールディングテストは、HLAとしてHLA-A*11:01を用い、エピトープペプチドとして表9-1に記載のものを用い、陽性コントロールペプチドに配列番号73のペプチドおよび陰性コントロールに配列番号40のペプチドを比較対象に用いたこと以外は、例4(2)と同様の方法を用いて行った。
(7)のフォールディングテストの結果に基づき、例4(3)と同様の手順にてPE標識HLA-テトラマー試薬を製造した。但し、エピトープペプチドとして配列番号60から配列番号72の13種類のBORIS特異的CTLエピトープ候補ペプチドを用い、HLAとしてHLA-A*11:01を用いた。その結果、配列番号68ではHLA-テトラマー試薬の製造ができなかった。したがって配列番号68を除く配列番号60から配列番号72のCTLエピトープ候補ペプチドとHLA-A*11:01をもつ12種類のHLA-テトラマー試薬を製造した。
HLA-A*11:01を保持していることがわかっている健康な成人2名を対象とし例3(5)と同様の手順で、CTLの誘導を行った。ただし、エピトープペプチドとして、HLA-A*11:01拘束性CTLエピトープ候補を4種類ずつ混合した4種類混合ペプチド1(配列番号60、配列番号63、配列番号66および配列番号70)または、4種類混合ペプチド2(配列番号61、配列番号64、配列番号67および配列番号71)または、4種類混合ペプチド3(配列番号62、配列番号65、配列番号69および配列番号72)を用いた。
BORIS sf5およびBORIS sf6特異抗体を取得する目的で、配列番号1および配列番号2からそれぞれ8~20個のアミノ酸で構成されるペプチド配列を合成し、このペプチドのC末端またはN末端にシステイン残基を付加し、定法に従ってKHL(Keyhole limpet hemocyanin)を結合させて免疫原に用いた。ウサギおよびモルモットに、隔週で、または毎週、4~6回免疫した。免疫終了後、各個体から採血し、これを免疫原に用いたペプチドで作製したアフィニティーカラムにより精製して特異抗体を得た。
特異性の検証は、BORIS sf5およびBORIS sf6をそれぞれ一過性に発現させた培養細胞293Tの細胞抽出液と未処理の293T細胞の細胞抽出液を用いて実施した。一過性に発現させたBORIS sf5およびBORIS sf6の遺伝子にはMyc Tag配列を付加しており、これに特異的なMyc Tag抗体を用いて陽性コントロールとした。
(1)siRNAの設計
下表に示すような配列を有するよう設計したBORISに対するsiRNAを、Lipofectamine RNAiMAXを用いるメーカーの使用説明書に記載のプロトコールに従って、MS751およびCaSkiの夫々にトランスフェクションした。細胞を、トランスフェクション後48時間で解析した。陰性対照としてTrilencer-27 Universal Scrambled Negative Control siRNA(SR30004、Origene)を用いた。
また、図16-1および16-2に示すように、CasKiおよびMS751の夫々におけるスフェア形成能については、siRNA2で顕著に抑制されていた(細胞増殖抑制の結果とは必ずしも一致しない)。
さらに、siRNA1~3のノックダウンは放射線耐性に関係しなかった(図17)。
図18から、BORIS発現が高いと生存率が著しく低くなることがわかる。それゆえ、BORISは有意な予後不良因子と認められる。
Claims (27)
- アイソフォームAまたはC、あるいはサブファミリー5または6に属するBORIS遺伝子を発現する細胞を特異的に認識するCTLを誘導する方法であって、以下の(a)または(b):
(a)前記BORISタンパク質の部分ペプチドであって、8~20アミノ酸長であり、HLA結合能を有するポリペプチド、
(b)上記(a)記載のポリペプチドの少なくとも一つをコードするポリヌクレオチド、
のいずれかと、末梢血リンパ球とを接触させることを含む、前記方法。 - in vitroで行われる、請求項1に記載の方法。
- 請求項1または2に記載の方法に用いるポリペプチドであって、配列番号1または配列番号2で表されるポリペプチドの部分ペプチドであり、8~20アミノ酸長であり、HLA結合能を有する、前記ポリペプチド。
- 8~11アミノ酸長である、請求項3に記載のポリペプチド。
- 配列番号1で表されるポリペプチドの部分ペプチドである、請求項3または4に記載のポリペプチド。
- 配列番号3、配列番号4、配列番号5または配列番号72で表される、請求項5に記載のポリペプチド。
- 配列番号2で表されるポリペプチドの部分ペプチドである、請求項3または4に記載のポリペプチド。
- 配列番号10で表される、請求項7に記載のポリペプチド。
- 請求項1または2に記載の方法に用いるポリペプチドであって、HLA-A11抗原結合能を有する、前記ポリペプチド。
- 配列番号65、配列番号66、配列番号67または配列番号72で表される、請求項9に記載のポリペプチド。
- 請求項1または2に記載の方法に用いるポリペプチドであって、HLA-A2抗原結合能を有し、配列番号4、配列番号5、配列番号10、配列番号47または配列番号57で表される、前記ポリペプチド。
- 請求項1または2に記載の方法に用いるポリペプチドであって、HLA-A24抗原結合能を有する、前記ポリペプチド。
- 配列番号3または10で表される、請求項12に記載のポリペプチド。
- 請求項3~13のいずれか一項に記載のポリペプチドにおいて1または複数のアミノ酸が付加、欠失、置換された、前記ポリペプチド。
- 請求項1または2に記載の方法に用いるポリヌクレオチドであって、請求項3~14のいずれか一項に記載のポリペプチドをコードする、前記ポリヌクレオチド。
- 請求項3~14のいずれか一項に記載のポリペプチドの少なくとも1つを有効成分として含む、細胞傷害性T細胞(CTL)誘導剤。
- 請求項16に記載のCTL誘導剤を有効成分として含む医薬組成物。
- 請求項16に記載のCTL誘導剤を有効成分として含む、がん幹細胞処置用組成物。
- 請求項16に記載のCTL誘導剤を有効成分として含む、がんの予防および/または治療用組成物。
- 請求項1または2に記載の方法で誘導した細胞傷害性T細胞(CTL)を有効成分として含む、がんの予防および/または治療用組成物。
- がんが、女性特有の臓器におけるがんまたは肺がんである、請求項19または20に記載のがんの予防および/または治療用組成物。
- 請求項15に記載のポリヌクレオチドを含有する発現ベクター。
- 請求項15に記載のポリヌクレオチド、または請求項22に記載の発現ベクターのいずれかを有効成分として含有する、がんの治療または予防のための医薬組成物。
- 請求項3~14のいずれか一項に記載のポリペプチドとHLAとを含有するHLA-テトラマー。
- 以下の(a)または(b):
(a)請求項3~14のいずれか一項に記載のポリペプチド
(b)上記(a)記載のポリペプチドの少なくとも1つをコードするポリヌクレオチド、
と、抗原提示能を有する細胞とを、in vitroで接触させることを含む、抗原提示細胞の製造方法。
- 配列番号1または配列番号2で表されるポリペプチドの少なくとも一部と特異的に結合する抗体。
- 請求項26に記載の抗体を含む、BORISタンパク質検出用キット。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2962558A CA2962558C (en) | 2014-09-24 | 2015-09-24 | A brother of the regulator of imprinted sites (boris)-derived tumor antigen peptide |
JP2016550373A JP6675987B2 (ja) | 2014-09-24 | 2015-09-24 | 腫瘍抗原ペプチド |
CN201580052966.2A CN107148469B (zh) | 2014-09-24 | 2015-09-24 | 肿瘤抗原肽 |
US15/514,169 US11028136B2 (en) | 2014-09-24 | 2015-09-24 | Tumor antigen peptide |
EP15843390.4A EP3199627B1 (en) | 2014-09-24 | 2015-09-24 | Tumor antigen peptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-194391 | 2014-09-24 | ||
JP2014194391 | 2014-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016047715A1 true WO2016047715A1 (ja) | 2016-03-31 |
Family
ID=55581234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/076994 WO2016047715A1 (ja) | 2014-09-24 | 2015-09-24 | 腫瘍抗原ペプチド |
Country Status (7)
Country | Link |
---|---|
US (1) | US11028136B2 (ja) |
EP (1) | EP3199627B1 (ja) |
JP (1) | JP6675987B2 (ja) |
CN (1) | CN107148469B (ja) |
CA (1) | CA2962558C (ja) |
TW (1) | TWI711633B (ja) |
WO (1) | WO2016047715A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110540588A (zh) * | 2018-05-28 | 2019-12-06 | 香港中文大学 | 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用 |
WO2020071554A1 (ja) | 2018-10-05 | 2020-04-09 | 北海道公立大学法人 札幌医科大学 | がん幹細胞特異的抗体 |
JP2021506269A (ja) * | 2017-12-13 | 2021-02-22 | イノビオ ファーマシューティカルズ,インコーポレイティド | Borisを標的とするがんワクチンおよびその使用 |
WO2021045224A1 (ja) * | 2019-09-04 | 2021-03-11 | 国立大学法人東海国立大学機構 | がん免疫療法等における免疫関連有害事象の予測 |
CN113053458A (zh) * | 2021-01-19 | 2021-06-29 | 深圳裕康医学检验实验室 | 一种肿瘤新生抗原负荷的预测方法及装置 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108250266A (zh) * | 2017-09-05 | 2018-07-06 | 首都医科大学附属北京佑安医院 | 一种hla-a11限制性gpc3源性多肽及包含它的疫苗 |
CN109988748A (zh) * | 2017-12-29 | 2019-07-09 | 深圳华大生命科学研究院 | 一种从til筛选肿瘤特异性t细胞的方法 |
CN113402590B (zh) * | 2021-07-14 | 2022-05-10 | 呈诺再生医学科技(珠海横琴新区)有限公司 | Khl多肽及其在制备tabp-eic细胞中的应用 |
CN114729029A (zh) * | 2021-12-23 | 2022-07-08 | 青岛华赛伯曼医学细胞生物有限公司 | 一种肿瘤抗原/mhc-i复合物及其制备方法和用途 |
CN115785208B (zh) * | 2022-06-10 | 2024-07-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标01及其用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010502192A (ja) * | 2006-08-31 | 2010-01-28 | アメリカ合衆国 | Borisアイソフォーム並びに疾患を検出及び治療する方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
AU2003242305A1 (en) * | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
ATE475430T1 (de) * | 2003-08-25 | 2010-08-15 | Univax Llc | Präventive krebsvakzine auf basis des boris (brother of regulator of imprinted sites) moleküls |
US7998486B2 (en) * | 2006-10-25 | 2011-08-16 | Newlink Genetics Corporation | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes |
US20090169613A1 (en) * | 2007-11-09 | 2009-07-02 | Reznik Boris N | Targeting of tumor stem cells through selective silencing of boris expression |
-
2015
- 2015-09-24 US US15/514,169 patent/US11028136B2/en active Active
- 2015-09-24 CA CA2962558A patent/CA2962558C/en active Active
- 2015-09-24 CN CN201580052966.2A patent/CN107148469B/zh active Active
- 2015-09-24 WO PCT/JP2015/076994 patent/WO2016047715A1/ja active Application Filing
- 2015-09-24 JP JP2016550373A patent/JP6675987B2/ja active Active
- 2015-09-24 EP EP15843390.4A patent/EP3199627B1/en active Active
- 2015-09-24 TW TW104131694A patent/TWI711633B/zh active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010502192A (ja) * | 2006-08-31 | 2010-01-28 | アメリカ合衆国 | Borisアイソフォーム並びに疾患を検出及び治療する方法 |
Non-Patent Citations (3)
Title |
---|
PUGACHEVA ELENA M. ET AL.: "The structural complexity of the human BORIS gene in gametogenesis and cancer", PLOS ONE, vol. 5, no. 11, 2010, pages e13872, XP055419657, Retrieved from the Internet <URL:http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0013872&representation=PDF> [retrieved on 20151028] * |
ROMAGNOLI GIULIA ET AL.: "EVALUATION OF THE POTENTIAL ROLE OF THE NEW CANCER-TESTIS ANTIGEN BORIS FOR THE DEVELOPMENT OF NOVEL STRATEGIES OF IMMUNOTHERAPY OF CANCER", RAPPORTI ISTISAN, vol. 6, no. 50, 2006, pages 36 - 40, XP009501169 * |
See also references of EP3199627A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021506269A (ja) * | 2017-12-13 | 2021-02-22 | イノビオ ファーマシューティカルズ,インコーポレイティド | Borisを標的とするがんワクチンおよびその使用 |
JP7485600B2 (ja) | 2017-12-13 | 2024-05-16 | イノビオ ファーマシューティカルズ,インコーポレイティド | Borisを標的とするがんワクチンおよびその使用 |
CN110540588A (zh) * | 2018-05-28 | 2019-12-06 | 香港中文大学 | 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用 |
CN110540588B (zh) * | 2018-05-28 | 2022-08-23 | 香港中文大学 | 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用 |
WO2020071554A1 (ja) | 2018-10-05 | 2020-04-09 | 北海道公立大学法人 札幌医科大学 | がん幹細胞特異的抗体 |
JPWO2020071554A1 (ja) * | 2018-10-05 | 2021-09-09 | 北海道公立大学法人 札幌医科大学 | がん幹細胞特異的抗体 |
EP3862366A4 (en) * | 2018-10-05 | 2022-06-29 | Sapporo Medical University | Cancer-stem-cell-specific antibody |
WO2021045224A1 (ja) * | 2019-09-04 | 2021-03-11 | 国立大学法人東海国立大学機構 | がん免疫療法等における免疫関連有害事象の予測 |
CN113053458A (zh) * | 2021-01-19 | 2021-06-29 | 深圳裕康医学检验实验室 | 一种肿瘤新生抗原负荷的预测方法及装置 |
CN113053458B (zh) * | 2021-01-19 | 2023-08-04 | 深圳裕康医学检验实验室 | 一种肿瘤新生抗原负荷的预测方法及装置 |
Also Published As
Publication number | Publication date |
---|---|
US11028136B2 (en) | 2021-06-08 |
JP6675987B2 (ja) | 2020-04-08 |
CA2962558C (en) | 2023-12-12 |
JPWO2016047715A1 (ja) | 2017-08-31 |
CN107148469A (zh) | 2017-09-08 |
CA2962558A1 (en) | 2016-03-31 |
EP3199627B1 (en) | 2021-04-07 |
CN107148469B (zh) | 2021-06-25 |
EP3199627A1 (en) | 2017-08-02 |
US20170298109A1 (en) | 2017-10-19 |
TWI711633B (zh) | 2020-12-01 |
TW201625663A (zh) | 2016-07-16 |
EP3199627A4 (en) | 2018-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6675987B2 (ja) | 腫瘍抗原ペプチド | |
JP5182770B2 (ja) | Mhc分子を結合する腫瘍関連ペプチド | |
JP6959597B2 (ja) | 腫瘍抗原ペプチド | |
JP6960179B2 (ja) | 腫瘍抗原ペプチド | |
JP7266834B2 (ja) | 腫瘍抗原ペプチド | |
KR20110134482A (ko) | Sox2 유래의 hla-a24결합성 암 항원 펩티드 | |
US9260499B2 (en) | Tumor antigen peptide and use thereof | |
WO2015005479A1 (ja) | 腫瘍抗原ペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15843390 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016550373 Country of ref document: JP Kind code of ref document: A Ref document number: 2962558 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15514169 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2015843390 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015843390 Country of ref document: EP |